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Summary 
Violacein and deoxyviolacein are promising therapeutics against pathogenic 
bacteria and viruses as well as tumor cells. In the present work, systems-wide 
metabolic engineering was applied to Escherichia coli for heterologous production 
of these high-value products. First, a high performance liquid chromatography 
method for accurate separation and quantification of violacein and deoxyviolacein 
was developed. Afterwards, a basic producer, E. coli dVio-1, that expressed the 
vioABCE cluster from Chromobacterium violaceum under control of the araBAD 
promoter and induction by L-arabinose, was constructed. Targeted intracellular 
metabolite analysis then identified bottlenecks in pathways that supply tryptophan, 
the major product building block of the natural products of interest. This was used 
for systems-wide engineering of serine, chorismate and tryptophan biosynthesis 
and the non-oxidative pentose-phosphate pathway, followed by elimination of L-
arabinose catabolism. Transferred to a glycerol-based fed-batch process, E. coli 
dVio-8 surpassed the gram scale and produced 1.6 g L-1 deoxyviolacein (> 99.5% 
purity). The created chassis of a high-flux tryptophan pathway was complemented 
by genomic integration of the vioD gene of Janthinobacterium lividum, which 
enabled exclusive production of violacein (710 mg L-1 with 99.8% purity). This 
demonstrates the potential of E. coli as a platform for production of tryptophan 
based therapeutics. 
 
 
  2 
Zusammenfassung 
Violacein und Deoxyviolacein sind vielversprechende Therapeutika gegen 
pathogene Bakterien und Viren als auch Tumorzellen. In der vorliegenden Arbeit 
wurde Escherichia coli zur heterologen Produktion dieser hochwertigen Produkte 
untersucht. Zuerst wurde eine HPLC-Methode für eine genaue Trennung und 
Quantifizierung von Violacein und Deoxyviolacein entwickelt. Anschließend wurde 
einer Basisstamm von E. coli, die die vioABCE Operon aus Chromobacterium 
violaceum unter der Kontrolle des araBAD-Promotor, konstruiert. Gezielte 
intrazelluläre Stoffwechselanalysen identifizierten dann Engpässe in den 
zuliefernden Routen der Biosynthese von Tryptophan, dem zentralen Baustein für 
das Produkt. Dieses Wissen wurde für die rationale Stammoptimierung genutzt. 
Durch die aufeinanderfolgende Optimierung von Serin-, Tryptophan- und 
Chorismat-Biosynthese sowie des nicht-oxidativen Pentose-Phosphat-Weges 
konnte eine umfassende Optimierung des Stoffflusses zum Zielprodukt erreicht 
werden. In einem Glycerin-basierten Fed-Batch-Verfahren, hat E. coli dVIO-8 den 
Gramm-Maßstab übertroffen (1,6 g L-1 Deoxyviolacein, >99,5% Reinheit). Das 
metabolische Chassis von E. coli mit einem High-Flux-Tryptophan-Weg wurde 
durch genomische Integration des vioD Genes aus Janthinobacterium lividum zur 
gezielten Produktion (710 mg L-1, 99,8% Reinheit) von Violacein weiterentwickelt. 
Die Ergebnisse zeigen darüber hinaus das große Potential von E. coli als 
Plattform für die Produktion Tryptophan-basierter Therapeutika. 
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1 Introduction  
1.1. Violacein and deoxyviolacein 
Violacein and deoxyviolacein are secondary metabolites produced by a 
diverse group of microorganisms. The pigments were firstly described in 1882 
when the compounds were extracted with ethanol and the spectrophotometric 
properties of the obtained solutions were analyzed (Boisbaudran, 1882). These 
molecules present blue/violet color, which facilitates the isolation of natural 
producer strains for further research and enable its use as a bio-dye that provides 
good color tone and stability (Shirata et al., 2000). Their biological role was studied 
using bacterial strains isolated from the environment (Matz et al., 2008). In order to 
analyze growth and survival rates of bacterivorous nanoflagellates, isolates of the 
violacein and deoxyviolacein producer strains Janthinobacterium lividum and 
Chromobacterium violaceum were used to feed these organisms. It was 
demonstrated that the uptake of less that than three pigmented bacterial cells 
caused cell death in less than 20 min to these microorganisms. The results of the 
study suggest that the production of the pigments is related to a defense 
mechanism against predation. In another study, it has been determined that the 
presence of J. lividum on the skin of the salamander species Plethodon cinereus 
increased the survival rates of this amphibian when exposed to the fungus 
Batrachochytrium dendrobatidis, the causative agent of the disease 
chytridiomycosis one of the causes for the decline in amphibian populations 
(Becker et al., 2009b). A threshold concentration of about 18 μM violacein 
prevented mortality caused by B. dendrobatidis. Due its biological properties, 
violacein and deoxyviolacein draw attention of researchers as possible candidate 
compounds for the development of drugs for cancer treatment among other 
biotechnological and medical applications.  
1.1.1. Biotechnological and therapeutic potential of violacein 
and deoxyviolacein  
Violacein and deoxyviolacein extracted from J. lividum are effective against 
Rosellinia necatrix, which is responsible for white root rot of mulberry. The use of 
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violacein and deoxyviolacein against this phytopathogenic fungi, demonstrated the 
fungicide potential of these compounds (Shirata et al., 2000). 
It was observed that a mixture of violacein and deoxyviolacein is effective 
against many gram-positive strains of microorganisms and to some extent against 
gram-negative. They are active against bacteria such as Bacillus licheniformis, 
Bacillus subtilis, Bacillus megaterium, Staphylococcus aureus, and Pseudomonas 
aeruginosa in concentrations ranging from 10-15 mg L-1. Depending on the 
concentration tested, the pigment mixture was able to cause growth inhibition to 
cell death (Nakamura et al., 2003; Nakamura et al., 2002). Particularly in the case 
of S. aureus, which is an opportunistic pathogen frequently involved in infections, 
alternative antibiotics for human treatment are in demand due to the increasing 
development of resistance against the current medicines available. The treatment 
of S. aureus human infections is done using antibiotics, such as methicillin or 
vancomycin. Strains resistant to methicillin have been described that could be 
treated with vancomycin; however, strains of S. aureus resistant to methicillin and 
vancomycin up to serum concentrations of 9.4 mg L-1 (Howe et al., 1998) were 
isolated, bringing concern to the medical community due to the lack of effective 
antibiotic alternatives for treatment (Sieradzki et al., 1999). Violacein loaded 
nanoparticles presented two to five times reduction of the minimal inhibitory 
concentration compared to the free form of the pigment against strains of S. 
aureus (Martins et al., 2011). 
Tuberculosis is a world-wide disease caused by Mycobacterium 
tuberculosis. In 2011, 8.7 million new cases were estimated and 1.4 million died, 
430,000 of which were also infected with HIV (WHO, 2012a). Conventional 
medication for treatment of tuberculosis is becoming ineffective, as occurrence of 
multidrug-resistant variants of Mycobacterium tuberculosis is increasing and 
reached 60,000 cases world-wide in 2011 (WHO, 2012a). Violacein exhibited 
activity against Mycobacterium tuberculosis (Mojib et al., 2010). The minimum 
inhibitory concentration of violacein extracted from Janthinobacterium sp. was 34.4 
mg L-1 for the virulent strain H37Rv demonstrating the potential of violacein for the 
treatment of tuberculosis.  
Experiments conducted to test the effect of violacein and deoxyviolacein 
mixtures in concentrations above 50 mg L-1 presented no growth inhibition or cell 
death against Escherichia coli HB 101 (Nakamura et al., 2003). Even when 
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violacein was loaded in polymeric poly-(D,L-lactide-co-glycolide) nanoparticles to 
improve solubility in water, no significant antibacterial activity occurred against E. 
coli in concentrations up to 68.5 mg L-1 (Martins et al., 2011). The ability of E. coli 
to cope with high violacein and deoxyviolacein concentrations is an important 
parameter regarding the potential utilization of this microorganism for production 
purposes, as further discussed below.   
Poliomyelitis is a highly infectious viral disease that can cause paralysis 
(Bonnet and Dutta, 2008) and affects mainly children under five years of age 
(WHO, 2012b). This disease can be prevented by vaccination; however, there is 
no specific treatment available (Bonnet and Dutta, 2008). In addition, the World 
Health Organization estimates that failure to eradicate polio in countries like 
Afghanistan, Nigeria, and Pakistan could make the disease spread all over the 
world within 10 years (WHO, 2012b). Experiments performed using extracts 
containing violacein and deoxyviolacein showed that these compounds can 
prevent human cell infection by the poliomyelitis virus (May et al., 1991). These 
extracts presented also activity against Herpes simplex virus cell infection (May et 
al., 1991). 
Violacein is also active against Leishmania amazonensis (Leon et al., 2001) 
and Trypanosoma cruzi (Durán et al., 1994) the causative agents of Leishmaniasis 
and Chagas diseases, respectively. These diseases are members of the group of 
neglected diseases (Trouiller et al., 2002) or more specifically, diseases for which 
no investments are made in research due to low profitability of the market formed 
by the low-income people that are affected by them.   
Leukemia is a type of cancer which affects the blood and the bone marrow. 
In the year 2000, it was estimated that this disease affected 255,932 people 
causing 209,328 deaths world-wide (Mathers et al., 2001). Violacein obtained from 
C. violaceum presented potential as a drug for leukemia treatment (da Silva Melo 
et al., 2000). It was effective against HL60 leukemic cells (Ferreira et al., 2004) an 
established model for studying myeloid leukemia. The mechanism by which 
violacein induced apoptosis in HL60 cells is related to the activation of the tumor 
necrosis factor (TNF) receptor signaling (Ferreira et al., 2004). In order to improve 
the efficiency of violacein against HL60 cells, the use of nanoparticles was tested. 
The fact that tumor cells have a higher ascorbic acid uptake rate motivated the use 
of violacein-loaded nanoparticles capped with ascorbic acid as a way to improve 
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the efficiency against tumor cells. This system was 2-fold more effective than free 
violacein as antitumoral drug (Martins et al., 2010). In another study (Gimenez et 
al., 2005), violacein complexed by cyclodextrin-thiol-protected gold nanoparticles 
presented improved water solubility as compared to free violacein. These 
nanoparticles presented reduced toxicity activity against normal V79 cells while 
maintaining the activity against myeloid leukemia HL60 cells. These results show 
that nanoparticles are an important tool for the targeted delivery of antitumoral 
compounds, such as violacein and deoxyviolacein, to cancer cells in order to 
reduce the side effects of chemotherapy.  
Colorectal cancer is the fourth most common cancer type (Boyle and 
Langman, 2000) and the third cause of cancer death (Parkin, 2001). It is estimated 
that colorectal cancer is responsible for 394,000 deaths annually affecting mainly 
Europe, North America, and Australasia. In the European Union it is the second 
cause of men death among the cancer types (Boyle and Langman, 2000). The 
chemotherapy employed for the treatment of colorectal cancer is done using 5-
fluorouracil (Heidelberger et al., 1957), which is the most widely used drug for this 
type of cancer (Gill et al., 2003), in combination with other compounds such as 
leucovorin (Machover, 1997). In a phase III study, it was demonstrated that 
patients treated with either a combination of 5-fluorouracil and leucovorin or 5-
fluorouracil, leucovorin and oxaliplatin presented 16 and 53% objective response, 
respectively (Giacchetti et al., 2000). The objective response was determined by 
extramural reviews of computed tomography scans. It has been demonstrated that 
violacein is an effective cytotoxic compound against colorectal cancer cells 
(Kodach et al., 2006). Violacein could induce apoptosis in colorectal cancer cells 
by blocking the phosphatidylinositol-3-kinase/Akt (Vivanco and Sawyers, 2002) 
activation and could increase the chemosensitivity of the cells to 5-fluorouracil 
when used in combination with this compound. The mechanism by which violacein 
induces death in the Caco-2 cell line, which is a model for colorectal cancer 
studies, involves the formation of reactive oxygen species that ultimately culminate 
in tumor apoptosis (De Carvalho et al., 2006). These results demonstrate the 
potential application of violacein as chemotherapeutic agent for colorectal cancer 
treatment. Moreover, violacein and deoxyviolacein were also able to inhibit 
hepatocellular carcinoma cell proliferation (Jiang et al., 2012). 
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In addition to in vitro studies on the antitumoral properties of violacein, in vivo 
studies were also performed using Ehrlich ascites tumor cells (EAT) as model 
(Bromberg et al., 2010). Experiments demonstrated that EAT cells were two times 
more sensitive to violacein than the normal cells. The experiments conducted 
using mice injected with EAT cells intraperitoneally showed that violacein doses 
ranging from 0.1 to 1 µg kg-1 significantly reduced tumor growth. Moreover, daily 
violacein doses of 1000 µg kg-1 did not cause toxicity to kidneys and liver when 
injected intraperitoneally. 
Antiulcerogenic activity of violacein (Durán et al., 2003) has been 
demonstrated in experiments using mice as model. Orally administered violacein 
significantly reduced gastric lessons. Further improvements of the protective effect 
of violacein were possible by using violacein beta-cyclodextrin (betaCD) inclusion 
complexes. In this case, reduction of gastric damage of about 85% was possible 
using violacein loaded betaCD inclusion complexes with 1:2 ratio. 
 
1.2. E. coli as industrial production host 
E. coli is one of the most used hosts for production of recombinant 
compounds in industry, due to its well known physiology, availability of tools for 
genetic manipulation, ease of scale-up, low-cost media and rapid growth  (Huang 
et al., 2012). Specifically, the strain K-12 has been established as standard and 
received guidelines for safety regarding therapeutics production. One third of the 
recombinant therapeutics approved by the US Food and Drug Administration and 
the European Medicines Agency are produced in E. coli (Huang et al., 2012). 
Some examples of approved recombinant therapeutics produced in E. coli are 
Ranibizumab (Lucentis), Somatropin (Accretropin), Certolizumab pegol (Cimzia), 
PEG interferon alfa-2b (PegIntron), Romiplostim (Nplate), and Interferon beta 1b 
(Extavia) Pegloticase (Krystexxa). Important advancements have been made in 
recent years towards the production of complex molecules that require disulfide 
bond formation and glycosylation. The functional expression of the N-linked 
glycosylation pathway of Campylobacter jejuni in E. coli opened up the possibility 
to generate compounds that require this important type of modification, frequently 
necessary in drugs for treatment of diseases and for research (Wacker et al., 
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2002). In addition to therapeutics production, E. coli is also an import host for 
production of a diverse group of chemicals for different purposes. 
Currently, an increasing tendency is observed regarding the use renewable 
resources for production of commodities and fine chemicals (Bozell and Petersen, 
2010). Due to concerns about negative environmental impacts of fossil based 
resources, as well as limitations in the availability or political instability in the 
producing countries, biotechnological based production appeared as a potential 
alternative to overcome these issues. Advancements in research along the years 
are making the economical feasibility of many biotechnological processes 
approach a state in which competition with the petrochemical industry can be 
considered. An indication of this trend is the growing global value of biotechnology 
industry, which increased from 54 billion dollars in 1999 to about 500 billion dollars 
in 2011 (Bruschi et al., 2011). An example of chemical produced in industrial scale 
by E. coli is 1,3-propanediol (Laffend et al., 1997), produced since 2006 with a 
45,000 tonne/year capacity (Burk, 2010). Another promising compounds, but not 
limited to, are fuels (1-propanol and 1-butanol), amino acids (L-threonine, L-valine, 
L-phenylalanine, L-tryptophan, and L-tyrosine), succinic acid, xylitol, and 1,4-
butanediol (Burk, 2010; Chen et al., 2013).  
 
1.3. Physiology and metabolism of E. coli 
In this section, a brief overview of the main pathways of the metabolism of E. 
coli will be given. Relevant aspects of the metabolism, e.g., transport and 
catabolism of glucose, glycerol, and L-arabinose, as well as the mechanisms of 
control of gene expression, will be presented. Finally, the L-tryptophan pathway will 
be covered concerning the relevant factors related to the improvement of the 
metabolic fluxes for biosynthesis of this fundamental amino acid for violacein and 
deoxyviolacein production. If not stated otherwise, the information presented in 
this section was based on the comprehensive works of (Keseler et al., 2005; 
Neidhardt et al., 1996). A simplified schematic presenting the transport systems of 
substrates, the central metabolism and biosynthesis of L-tryptophan is presented 
in Figure 1. 
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Figure 1. Central metabolism of E. coli and L-tryptophan pathway. Compound names: G6P 
(glucose 6-phosphate), F6P (fructose 6-phosphate), GAP (glyceraldehyde 3-phosphate), 3PG (3-
phosphoglycerate), PEP (phosphoenolpyruvate), PYR (pyruvate), ACCOA (acetyl-CoA), OAA 
(oxaloacetate), IND (indole), Rul5P (ribulose 5-phosphate), Xyl5P (xylulose 5-phosphate), Rib5P 
(ribose 5-phosphate), Sed7P (sedoheptulose 7-phosphate), E4P (erythrose 4-phosphate), Ser (L-
serine), DAHP (3-deoxy-D-arabino-heptulosonate-7-phosphate), CHO (chorismate), ANTH 
(anthranilate), Trp (L-tryptophan), IPA (indole-3-pyruvic acid imine), PDVA (protodeoxyviolaceinic 
acid), and AC (acetate). 
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1.3.1. Transport and metabolism of glucose, L-arabinose and 
glycerol 
Glucose is one of the main carbon sources utilized by E. coli. This 
microorganism is able to metabolize glucose, in addition to some salts, as energy 
and carbon source to synthesize the other compounds required for growth. 
Similarly, L-arabinose and glycerol can also serve this purpose. The catabolism of 
glucose initiates with its transport into the cell. The most used glucose transporter 
in E. coli is the phosphoenolpyruvate phosphotransferase system (PTS). In 
addition to glucose, the PTS is responsible for the transport of different 
compounds into the cell, such as mannitol and mannose. Some components of the 
PTS have a general purpose, while other proteins involved exhibit specificity for 
the target compound to be transported. The driving force required for this type of 
transport to take place is derived from phosphoenolpyruvate (PEP). The 
phosphate of this molecule is ultimately transferred to the respective sugar, during 
transport from the periplasm into the cytoplasm, releasing pyruvate as byproduct. 
The PTS responsible for the uptake of glucose is composed of free and 
membrane-bounded proteins. Enzyme I (EI) and the histidine protein (HPr) 
encoded by the genes ptsI and ptsH, respectively; are the free cytoplasmic 
general-use component part of the system. The sugar specific EII component has 
also a free and a membrane-bounded part. In the case of the glucose transport, 
these components are called IIAGlc or Crr and IICBGlc or PtsG encoded by the 
genes crr and ptsG, respectively. The transfer of the phosphate group of PEP to 
glucose occurs in following order: PEP → P-EI → P-HPr → P-EIIAGlc → P-EIICBGlc 
→ glucose-6-P. The general proteins encoded by the genes ptsH, ptsI, and crr of 
the glucose PTS are clustered in an operon. This operon is constitutively 
expressed at a basal level, but the level of gene expression is increased upon 
growth on PTS substrates. The ptsG gene is inducible by glucose in E. coli K-12. 
One of the possible explanations for the fact that the crr gene is expressed 
together with the general components EI and HPr can be the role that this protein 
plays on the transport of other compounds, such as trehalose and sucrose. In 
addition to glucose transport, the PTS has other important functions in E. coli. In a 
process called inducer exclusion, the EIIAGlc component interacts with proteins 
related to the metabolism of other carbon sources, e.g., glycerol and lactose, 
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inhibiting their activity and, consequently, the use of these compounds for growth. 
This process takes place when the cell is using a PTS carbohydrate as carbon 
source. Only if some of the above mentioned carbon sources is present that the 
EIIAGlc protein acts as inhibitor. This occurs because the non-phosphorylated form 
of EIIAGlc is able to bind and inhibit the activity of different proteins related to the 
catabolism of alternative carbon sources that are available during the metabolism 
of glucose. For instance, in the presence of glucose and glycerol, E. coli will first 
transport glucose using the PTS. During the glucose transport, the predominant 
form of the EIIAGlc protein will be non-phosphorylated, as the phosphates are now 
being transferred to the transported glucose. As glycerol is also present, the 
EIIAGlc protein is able to bind to the enzyme glycerol kinase, thereby inhibiting the 
phosphorylation of glycerol to glycerol-3-phosphate, which is the first intermediate 
metabolite of the glycerol catabolism. Another import role played by the PTS is the 
regulation of the adenylate cyclase activity. This enzyme is responsible for the 
biosynthesis of cyclic AMP (cAMP), an important signaling molecule. The 
interaction of cAMP with the transcriptional dual regulator CRP (cAMP receptor 
protein) yields the cAMP-CRP complex which acts globally in the control of 
transcription initiation in E. coli. The phosphorylated form of the EIIAGlc protein 
stimulates the hydrolysis of ATP by the adenylate cyclase for cAMP production. 
Therefore, as the concentration of phosphorylated EIIAGlc is low during glucose 
catabolism, adenylate cyclase activity will also be reduced; on the other hand, it is 
increased during catabolism of non-PTS compounds. This is the basis of the 
regulation mechanism known as catabolite repression. An example of carbon 
source subject to catabolite repression regulation is L-arabinose, as further 
discussed below. After glucose is transported into the cell with concomitant 
phosphorylation to glucose-6-phosphate, this metabolite can be promptly 
catabolized as carbon and energy source by the pathways of the central 
metabolism.  
 The transport of L-arabinose, contrary to glucose, does not rely directly on 
PTS. There are two transport systems for L-arabinose in E. coli, a system with 
high-affinity and another with low-affinity, which are encoded by the araFGH and 
araE genes, respectively. L-Arabinose transport through the araFGH system is 
driven by ATP hydrolysis, while the araE system consists of a symporter that relies 
on the electrochemical gradient of protons for the transport of L-arabinose through 
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the cell membrane. The araF gene is responsible for the production of a 
periplasmic binding protein. The araG and araH genes encode proteins 
responsible for the ATP binding and the membrane attachment, respectively. The 
regulation of gene expression in both systems is controlled by L-arabinose, AraC 
protein, CRP, and cAMP. When L-arabinose is present, the AraC protein changes 
its conformation to act as inducer of gene expression. This form of AraC interacts 
with the cAMP-CRP complex and the RNA polymerase, thereby inducing the 
expression of the araFGH and araE genes. Conversely, in absence of L-arabinose, 
the AraC protein acts as repressor of gene expression. This is a useful 
characteristic, as it allows the genes under control to be tight repressed or 
induced, fact that can play a major role regarding stability of heterologous gene 
expression in E. coli. As mentioned above, availability of the cAMP-CRP complex 
is required for induction of gene expression by the AraC protein. Here is where the 
catabolism of L-arabinose is affected by catabolic repression. If E. coli is 
metabolizing a PTS compound, the phosphorylation level of the protein EIIAGlc will 
be low, as the level of the EI protein will also be reduced due to the phosphate 
demand required by the substrate being transported. Due to the reversibility in the 
phosphorylation reactions in the PTS, the concentration of the P-EIIAGlc will 
decrease, thus reducing the activity of adenylate cyclase and, consequently, the 
intracellular concentration of cAMP. At this moment, the PTS can indirectly affect, 
provided that a PTS substrate is available, the transport of L-arabinose by 
repressing araFGH and araE expression. After transport into the cell, L-arabinose 
undergoes a series of modifications before is can be catabolized by the central 
metabolism of E. coli. Once L-arabinose is available in cytoplasm, it is metabolized 
by the enzymes L-arabinose isomerase, L-ribulokinase, and L-ribulose 5-
phosphate 4-epimerase of the araBAD operon. Similarly, the regulation of gene 
expression in this operon is subject to control by the AraC protein (Figure 2). In the 
first reaction, catalyzed by the enzyme L-arabinose isomerase, L-arabinose is 
converted to L-ribulose. This compound is phosphorylated by L-ribulokinase to 
yield L-ribulose 5-phosphate, which is finally converted to D-xylulose 5-phosphate 
and metabolized in central metabolism. 
Glycerol transport in E. coli occurs through a protein channel encoded by 
the glpF gene. This transport is mediated by facilitated diffusion, so that this 
carbohydrate can be moved in each direction through the cell membrane. Once 
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inside the cell, glycerol is phosphorylated by the enzyme glycerol kinase to 
generate glycerol-3-phosphate, using ATP as phosphoryl donor. The gplK gene is 
esponsible for the biosynthesis of glycerol kinase. This enzyme is allosterically 
inhibited by fructose-1,6-bisphosphate and the non-phosphorylated form of 
enzyme IIAGlc. Therefore, when E. coli is cultivated on glucose as carbon source,   
 
 
 
Figure 2. Structure of the AraC protein and mechanism of activation and repression of the araBAD 
promoter. A) Domains of the AraC monomer and the activator and repressor forms of the AraC 
dimmer. B) Organization of the PBAD and PC promoters. C) Mechanism of repression and activation 
of the araBAD promoter in the presence and absence of L-arabinose and the CRP protein. This 
figure was modified from (Moat et al., 2003).  
 
the catabolism of glycerol is inhibited. Once glycerol-3-phosphate is produced, it 
can be further metabolized in different ways, depending on the growth conditions. 
In aerobically growing cells, glycerol-3-phosphate is converted to 
dihydroxyacetone phosphate by the glycerol-3-phosphate dehydrogenase (GlpD), 
which is produced by the glpD gene. GlpD is associated with the cell membrane 
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and uses non-covalently bound FAD as cofactor to perform this oxidation reaction. 
In addition to dihydroxyacetone phosphate, two protons are released in the 
cytoplasm and ubiquinone is reduced in this reaction. During anaerobic cultivation, 
another version of the glycerol-3-phosphate dehydrogenase is expressed by the 
genes of the glpACB operon, and the electrons generated are transferred to either 
fumarate or nitrate. It has been demonstrated that E. coli lacking glycerol-3-
phosphate dehydrogenase, could recover its ability to grow on glycerol after 
selective pressure using this substrate. It was found that the glpA gene produced a 
glycerol dehydrogenase enzyme able to convert glycerol to dihydroxyacetone, 
which by activity of dihydroxyacetone kinase generated dihydroxyacetone 
phosphate, thus restoring growth capability on glycerol. Finally, dihydroxyacetone 
phosphate can be metabolized in the central metabolism. 
1.3.2. Metabolic pathways of the central metabolism 
The central metabolism comprises the set of pathways responsible for the 
generation of the metabolic precursors, energy, and reducing power to support 
biosynthetic reactions required for growth. From the intermediates of these 
pathways, the other components of the cell can be synthesized. In E. coli, these 
pathways are the Embden-Meyerhof-Parnas pathway (EMF or glycolysis), pentose 
phosphate pathway (PPP), and tricarboxylic acid cycle (TCA cycle). In cultivations 
of E. coli using glucose as carbon and energy source, about 50% of this sugar is 
oxidized to generate ATP/reducing power and the other 50% is converted into cell 
material. As discussed in the previous section, glucose is transported into the cell 
in the form of glucose-6-phosphate, which will be either metabolized through the 
PPP or the EMP pathway. 
The first reaction of the glucose-6-phosphate metabolism in the EMP 
pathway starts with its isomerization to fructose-6-phosphate. This reversible 
reaction is catalyzed by the enzyme phosphoglucose isomerase encoded by the 
pgi gene. Fructose-6-phosphate is subsequently phosphorylated to fructose-1,6-
biphosphate in an irreversible reaction in which ATP is used as the phosphoryl 
donor. The two variants of the enzyme fructose-6-phosphate kinase (PfkI and 
PfkII), responsible for this reaction, are encoded by the pfkA and pfkB genes in E. 
coli, respectively. About 90% of the enzyme activity of this reaction is performed 
by PfkI. This reaction is an important regulatory step of the EMP pathway. 
Introduction 
 
 15 
Fructose-6-phosphate kinase activity is stimulated by ADP and is allosterically 
inhibited by phosphoenolpyruvate. As the sum of the ATP, ADP, and AMP pools is 
almost constant in the cytoplasm of E. coli, an increased concentration of ADP is 
indication that the level of ATP was reduced, as many reactions involve the 
hydrolysis of ATP to ADP. One of the functions of the EMP pathway is the 
regeneration of ATP, thus explaining why this pathway is activated in the presence 
of ADP. On the other hand, if phosphoenolpyruvate accumulates, this indicates 
that the pathway must be inhibited, since this metabolite is one of the last 
intermediates produced in the EMP pathway. Due to the fact that the fructose-6-
phosphate kinase reaction is physiologically irreversible, another route to the 
biosynthesis of the precursor metabolite fructose-6-phosphate must exist to enable 
growth using other carbon sources, such as glycerol, that enter the central 
metabolism after the fructose-6-phosphate kinase reaction. This reverse reaction 
is catalyzed the enzyme fructose-1,6-biphosphate phosphatase, which is inhibited 
by AMP, thereby avoiding the generation of a futile cycle with fructose-6-
phosphate kinase. It was reported that strains of E. coli lacking the fbp gene 
encoding fructose-1,6-biphosphate phosphatase are unable to grow on glycerol as 
single carbon source, although other enzymes able to perform this reaction are 
present in the chromosome, e.g., GlpX. Once fructose-1,6-biphsophate is 
produced, it is cleaved to 3-phosphoglyceraldehyde and dihydroxyacetone 
phosphate. This splitting is catalyzed by the main fructose-1,6-biphosphate 
aldolase (FbaA) encoded by the gene fbaA. Dihydroxyacetone phosphate 
produced is also converted to 3-phosphoglyceraldehyde by the triosephosphate 
isomerase (tpiA gene). The next reaction of the EMP pathway is an oxidation, 
where NADH is generated. In this step, catalyzed by triosephosphate 
dehydrogenase (gapA gene), 3-phosphoglyceraldehyde is converted to 1,3-
biphosphoglycerate. This is the only reaction of the EMP pathway that regenerates 
NADH. In the next reaction, 1,3-biphosphoglycerate and ADP are the substrates 
used for a substrate level phosphorylation carried out by phosphoglycerate kinase 
(pgk gene) that yields ATP and 3-phosphoglycerate. The latter is converted to 2-
phosphoglycerate by phosphoglycerate mutase. This enzyme can be produced by 
the expression of the gpmA and gpmM genes generating non-homologous 
isofunctional enzymes. The enzyme produced by gpmA is 2,3-bisphosphoglyerate-
dependent and presents higher specific activity. The enzyme enolase (eno gene) 
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dehydrates the 2-phosphoglycerate to phosphoenolpyruvate, which is finally used 
in the second substrate level phosphorylation to produce pyruvate and ATP by the 
activity of the pyruvate kinase. In E. coli, pyruvate kinase I and pyruvate kinase II 
are encoded by genes pykF and pykA, respectively. This reaction is also 
physiologically irreversible and is positively regulated by the presence of fructose-
6-phosphate. Overall, the EMP pathway generates two pyruvate molecules, two 
ATP, two NADH, and two H+ for each glucose molecule catabolized and the 
respective ADPs, Pis, and NAD+s processed.  
Another important pathway of the central metabolism of E. coli is the PPP. 
This pathway plays an important role in the regeneration of NADPH and the supply 
of metabolic precursors to the cell. In order to better comprehend how PPP works, 
it is convenient to divide the whole pathway in three parts. The first part involves 
the oxidation of glucose-6-phosphate through three biochemical reactions. Initially, 
glucose-6-phosphate is converted to 6-phosphogluconolactone, which is 
subsequently metabolized to 6-phosphogluconate. In the final step of the first part, 
ribulose-5-phosphate is formed from the latter metabolite. The enzymes catalyzing 
these reactions are glucose-6-phosphate dehydrogenase (zwf gene), 6-
phosphogluconolactonase (pgl gene), and 6-phosphogluconate dehydrogenase 
(gnd gene); respectively. In the Zwf and Gnd reactions, NADPH is regenerated 
from NADP+. The Gnd reaction produces also CO2 by the decarboxylation of the 
C1 of glucose-6-phosphate. The PgI reaction is physiologically irreversible and 
there are no alternative enzymes able to perform this reaction backwards directly 
in E. coli. However, carbon flowing through these metabolic steps can be recycled 
back to glucose-6-phosphate using an alternative route, as explained below. The 
second part of the PPP is the reversible isomerization of ribulose-5-phosphate to 
either xylulose-5-phosphate or ribose-5-phosphate, catalyzed by the enzymes 
ribulose-5-phsopate epimerase (rpe gene) and ribose-5-phosphate isomerase 
(rpiA and rpiB genes), respectively. The ribose-5-phosphate isomerase A of E. coli 
is constitutively expressed and performs about 99% of the isomerization, while 
ribose-5-phosphate isomerase B can replace the RpiA only if it is induced. The 
part three of the PPP involves a series of reversible carbon transfers between 
ribose-5-phosphate and xylulose-5-phosphate to generate exclusive PPP 
intermediates, as well as metabolites shared with the EMP pathway. It starts with 
the transfer of two carbons from xylulose-5-phosphate to ribose-5-phosphate 
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generating sedoheptulose-7-phosphate and glyceraldehyde-3-phosphate. This 
reaction is performed by the enzyme transketolase, which has two variants in E. 
coli, TktI and TktII. Transketolase I (tktA gene) has most of the enzyme activity. In 
the next reaction of the third part of PPP, three carbons of sedoheptulose-7-
phosphate are transferred to glyceraldehyde-3-phosphate to form erythrose-4-
phosphate and fructose-6-phosphate. This reaction is catalyzed by both 
transaldolase A (talA gene) and B (talB gene). The final step is the transketolase 
mediated transfer of two carbons of xylulose-5-phosphate, which was produced in 
the second part of PPP, to the erythrose-4-phosphate to produce fructose-6-
phosphate and glyceraldehyde-3-phosphate. Due to the reversibility of the 
phosphoglucose isomerase reaction of the EMP pathway, fructose-6-phosphate 
produced in the PPP can be converted back to glucose-6-phosphate. Therefore, if 
the oxidative part of the PPP is necessary, e.g., high NADPH demand, fructose-6-
phosphate can be redirected to meet this requirement. Similarly to fructose-6-
phosphate, glyceraldehyde-3-phosphate produced in the PPP can also be 
metabolized though the EMP pathway. Taking into account the above mentioned 
reversibility of the phosphoglucose isomerase, the overall stoichiometry of the 
PPP is the production of 3 CO2, 1 glyceraldehyde-3-phosphate, 6 H
+ and the 
regeneration of 6 NADPH for each glucose-6-phosphate molecule processed. As 
can be seen, the EMP pathway and the PPP are interconnected in such a way that 
the cell has flexibility to control biosynthesis of precursors and NADPH 
regeneration. In continuation of the analysis of the central metabolism, the fate of 
the pyruvate produced in the EMP pathway is addressed. 
Different pathways are able to metabolize pyruvate depending on the 
growth conditions. In anaerobiosis, pyruvate reacts with coenzyme A (CoA) to 
form acetyl-CoA and formate by the activity of the pyruvate-formate lyase (PflB). 
During aerobic growth, the pyruvate dehydrogenase complex is responsible for the 
conversion of pyruvate to acetyl-CoA and CO2, converting NAD
+ to NADH. This 
complex is inhibited by NADH and acetyl-CoA, and is stimulated by PEP and 
AMP. A third metabolic fate of pyruvate is its conversion to acetate through the 
activity of the pyruvate oxidase (poxB gene) to acetate and CO2. The acetate is 
released into the culture medium, but can later be metabolized to acetyl-CoA by 
two routes. Acetyl-CoA synthetase (acs gene) converts acetate to acetyl-CoA 
using ATP and CoA; releasing AMP and diphosphate. The other route is the ack-
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pta pathway. The enzymes involved, acetate kinase A (ackA gene) and phosphate 
acetyltransferase (pta gene), are constitutively expressed in an operon that 
enables the reversible conversion of acetate to acetyl-CoA. In this pathway, 
acetate is first converted to acetyl phosphate (AckA activity) with ATP as the 
phosphoryl donor; and the latter product reacts with CoA (Pta activity) to form 
acetyl-CoA. In aerobic conditions the acetyl-CoA formed is subsequently 
metabolized in the TCA cycle. 
The TCA cycle starts with the irreversible condensation of acetyl-CoA and 
oxaloacetate forming citrate. The enzyme citrate synthase (gltA gene) that 
catalyzes this reaction is allosterically inhibited by NADH and α-ketoglutarate. The 
citrate formed is converted to isocitrate, with cis-aconitate as intermediate. Two 
enzymes can perform this step, the aconitate hydratase 1 and 2, which are 
encoded by the genes acnA and acnB, respectively. Isocitrate is then oxidized to 
α-ketoglutarate generating CO2 and NADPH from NADP
+. The enzyme isocitrate 
dehydrogenase (icd) that performs this reaction is regulated by 
phosphorylation/dephosphorylation, enabling the fast shift between the TCA cycle 
and the glyoxalate bypass, as discussed in the next section. Subsequently, 
succinyl-CoA is formed from α-ketoglutarate, releasing CO2 and NADH. The 
reaction is carried out by the α-ketoglutarate dehydrogenase complex (sucA, sucB, 
lpd genes). As can be seem, two carbons were released as CO2 up to this point of 
the TCA cycle. In order to function as a cycle, the carbons of the succinyl-CoA are 
conserved until the formation of oxaloacetate, which will be used to restart the 
cycle. The unique substrate level phosphorylation of the TCA cycle is catalyzed by 
the succinyl-CoA synthetase (sucD and sucC genes), where succinyl-CoA is 
converted to succinate, having CoA and ATP as products. In this reaction, 
inorganic phosphate is used to phosphorylate ADP to form ATP. Succinate is 
oxidized to fumarate, which is hydrated to L-malate. Finally, oxaloacetate is formed 
by the oxidation of L-malate. The first of the last three reactions is performed by 
the enzyme succinate dehydrogenase (sdhABCD genes), which yields FADH2 
from FAD, while conversion of fumarate to L-malate is done by the fumarases A, 
B, and C (fumA, fumB, fumC genes). The fumarases A and B are sensitive to 
oxidative agents. In conditions of oxidative stress, the fumarase C catalyzes the 
formation of L-malate. Formation of oxaloacetate can be performed independently 
by the enzymes malate:quinone oxidoreductase (mqo gene) or malate 
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dehydrogenase (mdh gene), releasing a quinol and NADH, respectively. The 
carbon balance of the TCA cycle demonstrates that, for each acetyl-CoA 
processed through, two molecules of CO2 are formed, and the oxaloacetate used 
in the beginning is cycled back to be used in the next round. 
Another metabolic important pathway connected to glycolysis and PPP is 
the Entner-Doudoroff pathway (ED pathway). This pathway plays an important role 
during growth on substrates, such as gluconate, glucuronate, or galacturonate. It 
is connected to the PPP at the level of 6-phosphogluconate. In the ED pathway, 
this metabolite is firstly converted to 2-dehydro-3-deoxy-D-gluconate 6-phosphate, 
and then is split to pyruvate and 3-phosphoglyceraldehyde. These products are 
metabolized in the other pathways of the central metabolism. The two reactions 
described above are catalyzed by the enzymes phosphogluconate dehydratase 
(edd gene) and 2-keto-3-deoxygluconate 6-phosphate aldolase (eda gene), 
respectively.  
The glycolysis, PPP, and the TCA cycle provide the twelve precursor 
metabolites required to the biosynthesis of the building blocks (Table 1). From 
these building blocks, all the major components of the cell, e.g., proteins, 
nucleotides, lipids, polysaccharides; are produced. Another important category of 
biochemical reactions is required to ensure that the precursor metabolite 
availability meets the cell requirements. These metabolic steps, known as 
anapleurotic reactions, are discussed in more detail in the next section.  
Table 1. Precursor metabolites required fort he biosynthesis of the building blocks. 
Precursor metabolites Building blocks 
glucose-6-phosphate Glycogen, lipopolysaccharides 
fructose-6-phosphate Cell wall 
ribose-5-phosphate Histidine, phenylalanine, tryptophan, nucleotides 
erythrose-4-phosphate Phenylalanine, tryptophan, tyrosine 
glyceraldehyde-3-phosphate Lipids 
3-phosphoglycerate Cysteine, glycine, serine 
phosphoenolpyruvate Tyrosine, tryptophan 
pyruvate Alanine, isoleucine, lysine, leucine, valine 
acetyl-CoA Leucine, lipids 
α-ketoglutarate Glutamate, glutamine, arginine, proline 
succinyl-CoA Methionine, lysine, tetrapyrroles (e.g., heme) 
oxaloacetate Asparagine, aspartate, isoleucine, lysine, methionine, 
threonine, nucleotides 
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1.3.3. Anapleurotic reactions 
In order to be able to grow, E. coli drains precursor metabolites from the 
central metabolism to produce the required building blocks. Depending on the 
substrate used as carbon source and the growth conditions, e.g., aerobic or 
anaerobic, limitations may occur in the pathways of the central metabolism due to 
this demand. For instance, intermediates of the TCA cycle are used for 
biosynthesis of building blocks. In cells growing on a substrate like glucose, the 
TCA cycle would run out of precursor metabolites, as there is not net synthesis of 
these compounds in the cycle. In order to overcome this limitation, special types of 
reactions, known as anapleurotic reactions, accomplish the task of replenishing 
these intermediates. 
In aerobic growth on glucose, about 30% of glucose-6-phosphate is 
metabolized through the PPP and 70% in the glycolysis. Therefore, the precursor 
metabolites of these pathways are constantly produced. To replenish the TCA 
cycle intermediates, the enzyme phosphoenolpyruvate carboxylase (ppc gene) 
performs the carboxylation of phosphoenolpyruvate producing oxaloacetate and 
inorganic phosphate. The activity of this enzyme is also required when the cell is 
growing on glycerol or L-arabinose. During aerobic growth on glucose, E. coli 
secretes acetate into the culture medium. After glucose is consumed, the 
accumulated acetate starts to be metabolized as carbon source. Acetate is 
converted to acetyl-CoA, as described in the previous section, which can be used 
as single carbon source. Initially, acetyl-CoA is processed in the TCA cycle. As 
explained above, the TCA cycle loses carbon as CO2. In this case, as acetyl-CoA 
is the only carbon source, the cycle would stop, as the oxaloacetate pool would be 
completely drained for production of building blocks. To circumvent this limitation, 
the cell utilizes the glyoxylate bypass (also called glyoxylate cycle). Initially, acetyl-
CoA is converted to isocitrate though the TCA cycle. The glyoxylate bypass starts 
from this intermediate, by converting it to succinate and glyoxylate. The latter is 
subsequently fused to another acetyl-CoA molecule to generate malate and CoA. 
The two enzymes that perform these reactions are the isocitrate lyase (aceA gene) 
and malate synthase (aceB gene), respectively. Malate is then converted to 
oxaloacetate in the TCA cycle, which is used to produce phosphoenolpyruvate by 
the ATP-dependent activity of the phosphoenolpyruvate carboxykinase (pck gene). 
Phosphoenolpyruvate in then metabolized in the gluconeogenesis, which is 
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essentially the reverse form of the glycolysis where the irreversible step of 
converting fructose-1,6-biphosphate to fructose-6-biphosphate is overcome 
through the activity of fructose-1,6-biphosphate phosphatase, as explained in the 
previous section. E. coli is also able to grow using pyruvate as carbon source. This 
carbon source can be converted to acetyl-CoA by the pyruvate dehydrogenase 
complex. Interestingly, this metabolite is not processed to enable growth the same 
way that acetate is processed. From pyruvate, phosphoenolpyruvate can be 
produced by the activity of the ATP-driven phosphoenolpyruvate synthetase (ppsA 
gene). The intermediates of the TCA cycle are replenished through 
phosphoenolpyruvate carboxylase activity, the same way that occurs during 
growth using glucose as carbon source. In continuation of the description of the 
metabolism of E. coli, the important pathway of L-tryptophan biosynthesis, the 
violacein and deoxyviolacein precursor, will be addressed in more detail in the 
next section. 
 
1.3.4. L-Tryptophan biosynthesis     
L-Tryptophan is one of the three aromatic amino acids produced by E. coli. 
The biosynthesis of these amino acids has the chorismate pathway in common. 
From this metabolite, production of L-tryptophan proceeds independently, while L-
tyrosine and L-phenylalanine share the chorismate-derived prephenate as the last 
common intermediate. 
 The chorismate pathway starts with the condensation of erythrose-4-
phosphate and phosphoenolpyruvate, producing 3-deoxy-D-arabino-
heptulosonate-7-phosphate and inorganic phosphate. Three different 2-dehydro-3-
deoxyphosphoheptonate (DAHP) aldolase isozymes, also known as DAHP 
synthases, conduct this reaction in E. coli. These enzymes, encoded by the genes 
aroF, aroG, and aroH, are feedback inhibited by L-tyrosine, phenylalanine, and L-
tryptophan, respectively. The DAHP is then converted to 3-dehydroquinate by 
dehydroquinate synthase (aroB gene), which is subsequently used to produce 3-
dehydroshikimate through the activity of the 3-dehydroquinate dehydratase (aroD 
gene). Shikimate is produced from 3-dehydroshikimate by two shikimate 
dehydrogenases, one that utilizes NADPH (aroE gene) and another able to use 
either NADPH or NADH (ydiB gene). ATP-driven phosphorylation of shikimate by 
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shikimate kinase yields shikimate-3-phosphate. Two variants of this enzyme are 
present in E. coli, shikimate kinase I (aroK gene) and II (aroL gene).  Shikimate 
kinase II is the dominant enzyme in this conversion and its expression is controlled 
by the TyrR and TrpR repressors. Next, 5-enolpyruvyl-shikimate 3-phosphate is 
formed by the fusion of shikimate-3-phosphate and phosphoenolpyruvate, 
releasing inorganic phosphate. This condensation is catalyzed by 3-
phosphoshikimate-1-carboxyvinyltransferase (aroA gene). The final step of the 
pathway is the chorismate synthase (aroC gene) catalyzed removal of inorganic 
phosphate from 5-enolpyruvyl-shikimate 3-phosphate to produce chorismate, the 
first intermediate of L-tryptophan biosynthesis. 
 All the genes required for the production of L-tryptophan are encoded in the 
operon trpEDCBA in E. coli. The transcription of this operon is repressed by the 
TrpR repressor (trpR gene) and also by attenuation involving the trpL gene that 
encodes the leader peptide. The enzyme anthranilate synthase catalyzes the first 
reaction, where chorismate is converted to anthranilate. The genes trpED encode 
the two components of anthranilate synthase responsible for the transfer of the 
amino group of glutamine to chorismate, releasing glutamate. In this reaction, a 
part of the chorismate molecule is released in the form of pyruvate to conclude 
anthranilate production. Anthranilate synthase is feedback-inhibited by L-
tryptophan. Once anthranilate is produced, it is fused with 5-phospho-α-D-ribose 1-
diphosphate to generate N-(5-phosphoribosyl)-anthranilate. This reaction is 
interesting because it is performed by an enzyme, the anthranilate phosphoribosyl 
transferase, which is also encoded by the trpD gene. Therefore, the TrpD enzyme 
plays two roles in the L-tryptophan biosynthesis. In combination with TrpE, in is 
involved in the first reaction of the L-tryptophan biosynthesis, while alone it is 
responsible for the second reaction. Similarly, the next two reactions of the 
pathway are catalyzed by another bifunctional enzyme encoded by the trpC gene. 
First, TrpC acts as phosphoribosylanthranilate isomerase and later as indole-3-
glycerol phosphate synthase to produce 1-(o-carboxyphenylamino)-1'-
deoxyribulose 5'-phosphate and indole-3-glycerol-phosphate (in addition to CO2), 
respectively. The final two steps of the L-tryptophan biosynthesis are conducted by 
the L-tryptophan synthase. This bifunctional enzyme converts the indole-3-
glycerol-phosphate to indole and glyceraldehyde-3-phosphate. The former is then 
fused to L-serine to yield L-tryptophan. L-Tryptophan synthase contains two dimers 
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of α (trpA gene) and β (trpB gene) subunits. By analyzing the biosynthesis of L-
tryptophan since the metabolic precursors, it can be determined that for each 
molecule of this amino acid one erythrose-4-phosphate, two 
phosphoenolpyruvates, one L-glutamine, one phosphoribosyl-5-pyrophosphate, 
and one L-serine molecules are necessary.  
 The L-tryptophan pathway has been extensively studied along the last 
decades. In these studies, the important points of metabolic regulation related to 
the production of L-tryptophan were precisely identified in E. coli. This knowledge 
has enabled the rational engineering of strains able to accumulate this amino acid 
at high titers, thereby allowing its widespread use for different purposes, such as a 
feed additive and in the pharmaceutical industry (Shen et al., 2012). Basically, 
metabolic engineering strategies used develop L-tryptophan producing strains of 
E. coli rely on i) elimination of repressors of the pathways involved, ii) elimination 
of attenuators, iii) removal of feedback-inhibition of the enzymes involved, iv) 
overexpression of target pathways, and v) removal of competing pathways (Ikeda, 
2006; Sprenger, 2007). Starting from a well known E. coli strain, e.g., MG1655, 
deletion of the repressor of the trpEDCBA operon, trpR gene, permits the L-
tryptophan genes to be expressed to a higher level. The next beneficial genetic 
modification to allow high level expression of this operon is the removal of leader 
peptide encoded by the trpL gene. At this point, the obtained strain would be able 
to accumulate a higher level of L-tryptophan in the cytoplasm. However, high L-
tryptophan pools trigger the expression of the tryptophanase (tnaA gene), which 
degrades L-tryptophan to indole, pyruvate and NH4
+. To avoid this, the tnaA gene 
also needs to be removed. Next, the feedback inhibition of anthranilate synthase 
should be addressed, by inserting the necessary mutations that enable the 
enzyme to become insensitive to L-tryptophan inhibition. At this point, the 
limitations in the availability of the other precursors required for production can 
also be tackled. For each L-tryptophan produced, one L-serine molecule is 
required. If the production of this amino acid can not cope with the demand 
required for L-tryptophan production, the necessary modifications to improve of the 
L-serine pathway have to be made. The same strategy used for the L-tryptophan 
pathway can be used here; specifically, overexpression of the L-serine pathway 
genes, and removal of feedback-inhibition of the first reaction of L-serine 
production catalyzed by the enzyme D-3-phosphoglycerate dehydrogenase (serA 
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gene). By streaming up the L-tryptophan pathway, the next component required for 
tryptophan biosynthesis is N-(5-phosphoribosyl)-anthranilate. Production of this 
molecule can also be improved by modifications of the phosphoribosyl anthranilate 
transferase expression and removal of L-tryptophan sensitivity (Aiba et al., 1982). 
At this point, the availability of chorismate must be addressed, as its production is 
tightly regulated in E. coli. Supply of this intermediate is limited at the DAHP 
synthase level. A general strategy to overcome this limitation is the overexpression 
of feedback-resistant variants of the aroF, aroG, and aroH genes. Finally, genetic 
modifications can be done to increase the pool of the precursors of the central 
metabolism erythrose-4-phosphate and phosphoenolpyruvate. In the case of 
erythrose-4-phosphate, overexpression of the tktA gene, or phosphoglucose 
isomerase deletion were reported as beneficial, whereas phosphoenolpyruvate 
availability can be improved by employing different strategies, such as deletion of 
phosphoenolpyruvate carboxylase or the pyruvate kinases, overproduction of the 
phosphoenolpyruvate carboxykinase or phosphoenolpyruvate synthetase. Another 
important aspect relevant to the availability of phosphoenolpyruvate is the type of 
substrate used during the production. For instance, glucose is transported into the 
cell by the PTS, which is phosphoenolpyruvate dependent. For each glucose 
molecule transported, one phosphoenolpyruvate molecule is converted to 
pyruvate, thereby limiting phosphoenolpyruvate supply for L-tryptophan production. 
This problem can be overcome by modifying the glucose transport system or using 
a non-PTS substrate, e.g., glycerol. 
 
1.4. Escherichia coli as host for violacein and deoxyviolacein 
production 
Escherichia coli is one of the most studied microorganisms. Due to the basic 
research carried out by different groups, a comprehensive systemic understanding 
of the metabolism in the genomic, transcriptomic, proteomic and fluxomic levels 
permits the systems-wide engineering of E. coli for different purposes. In this 
section, a brief overview of tools available for optimization of this microorganism 
for production of metabolites, such violacein and deoxyviolacein, and the 
heterologous production of these drugs, will be given.    
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1.4.1. Tools for genetic engineering 
Many methods have been developed for the manipulation of genetic 
material of E. coli, each one presenting its peculiarities. For the sake of metabolic 
engineering studies, methods of molecular biology that allow cloning, insertion, 
deletion and modification of genes in chromosome or in plasmids are mandatory. 
One of the techniques that allow these types of genetic modification is known as 
recombineering. Recombineering stands for recombination mediated genetic 
engineering (Ellis et al., 2001). The advantage of this method is the fact that 
homologous recombination of single or double-stranded DNA molecules bearing 
homologous regions as short as 30 bp is possible (H0 and H1 in Figure 3). The 
necessary homologous DNA sequences can be inserted in other DNA molecules 
by polymerase chain reaction (PCR) using primers designed to include these 
regions (Figure 3A). This facilitates the efforts to obtain the linear DNA that will be 
used for the recombination. After obtaining the desired linear DNA molecule, the 
next step is its introduction into E. coli cells for subsequent recombination (Figure 
3B, C, and D). Normal E. coli cells have the RecBCD and SbcCD nucleases that 
degrade linear DNA once it is inserted into the cells. In order to avoid this and 
permit the recombination event to take place, the recombineering method uses the 
Red proteins Exo, Beta, and Gam from phage λ. After inserting the linear DNA into 
E. coli expressing the λ Red proteins, Gam inhibits RecBCD and SbcCD activities, 
thereby allowing homologous recombination to take place by action of Exo and 
Beta. The function of Exo is the degradation of dsDNA to release ssDNA that will 
be used for recombination. In case the cell is transformed with ssDNA instead of 
dsDNA, the activity of Exo is not necessary. Finally, Beta can bind to the ssDNA 
for recognition of the homologous sequences and subsequent recombination 
event. Beta also prevents ssDNA degradation by the action nucleases. Expresion 
of Red proteins in E. coli can be done using the plasmid pKD46 (Datsenko and 
Wanner, 2000) (Figure 3B and C). By using the recombineering technology, 
desired modifications of the E. coli genome can be performed. In order to select 
the clone containing the desired modification, a selection marker is usually 
employed (Figure 3A). This maker can be a gene conferring antibiotic resistance 
or another phenotype that permits the desired clone to be differentiated from the 
other cells. For instance, the inactivation of genes related to production of amino  
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Figure 3. Overview of genetic modification using the recombineering methodology followed by 
marker removal. 
 
acids produces auxotrophic mutants. Studies in which the objective is the isolation 
of strains that present enzymes with feedback resistance take advantage of the 
auxotrophic mutants to select feedback resistant strains. Provided that a feedback 
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resistant variant of the target genes is available, this can be done by restoring this 
gene variant to the auxotrophic mutants by recombineering. Afterwards, by 
cultivating the recombinants in medium containing a suicide inhibitor for the 
respective enzyme, clones containing the desired variant of the genes can be 
selected. The advantage of this strategy is that no extra DNA sequences are left in 
the chromosome after the modification. Alternatively, removal of markers can be 
performed by flanking them with short direct repeats (FRT sites) sequeces that 
can be later used to remove the DNA between the FRTs by the yeast Flp 
recombinase (Figure 3E and F) of the pCP20 plasmid (Cherepanov and 
Wackernagel, 1995). 
 
1.4.2. Heterologous production of violacein and deoxyviolacein 
The violacein and deoxyviolacein biosynthetic routes are encoded by the 
vioABCDE operon. In a series of studies, the intermediates of the pathways and 
the function of the enzymes have been identified (Asamizu et al., 2007; Pemberton 
et al., 1991; Sánchez et al., 2006; Shinoda et al., 2007). Shortly, the biosynthesis 
starts from L-tryptophan, which is converted by VioA into indole-3-pyruvic acid 
imine (Figure 4). Two of these intermediates are fused by concomitant action of 
VioB and VioE, to yield protodeoxyviolaceinic acid, which is then further processed 
into violacein by the enzymes VioD and VioC. In contrast, deoxyviolacein 
biosynthesis only requires VioC activity in the final step so that this derivate can be 
obtained in pure form via inactivation of the vioD gene, resulting in a shortened 
operon that contains only vioABCE (August et al., 2000).    
Due to the therapeutic potential of violacein and deoxyviolacein, their 
production in different natural strains has been thoroughly investigated (Ahmetagic 
and Pemberton, 2010; August et al., 2000; Jiang et al., 2012; Jiang et al., 2010; 
Mendes et al., 2001; Yang et al., 2007), but was found limited by low productivity 
(Yang et al., 2011) of the natural producers. Particularly in the case of 
deoxyviolacein, the levels in natural producers are low, comprising only 10% of the 
overall pigment produced (Hoshino, 2011). Isolates of the best-studied natural 
producers Chromobacterium violaceum and Janthinobacterium lividum cause rare 
but highly deathly infections in humans (Patjanasoontorn et al., 1992; Ti et al., 
1993), which obviates their use in pharmaceutical biotechnology. This strongly 
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drives the overexpression of the vioABCDE operon in suitable recombinant hosts 
that exhibit fast growth on simple media, straightforward genetic accessibility, well-
understood physiology and that are particularly accepted as safe drug producers. 
A study have indeed demonstrated recombinant violacein production in Citrobacter 
freundii and Enterobacter aerogenes (Yang et al., 2011). Pioneering studies 
 
 
Figure 4. Biosynthetic pathways for violacein and deoxyviolacein. 
 
reported successful heterologous expression of the vioABCDE pathway also in 
Escherichia coli (August et al., 2000; Pemberton et al., 1991). This was an early 
milestone for safe production, as E. coli K-12 is widely accepted in industrial 
biotechnology (Huang et al., 2012) and employed for production of compounds 
used for human treatment (Ferrer-Miralles et al., 2009). In addition, E. coli K-12 
strains are efficient in synthesizing L-tryptophan (Azuma et al., 1993; Berry, 1996), 
the precursor of violacein and deoxyviolacein. The product titers of these 
recombinant violacein and deoxyviolacein producers are still limited, probably due 
to the rather local pathway engineering, restricted to exclusive expression of the 
heterologous biosynthetic chain. At this stage, a next level of production strains 
with improved performance might be expected from systems metabolic 
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engineering on a global scale (Becker and Wittmann, 2012), which explores and 
recruits the complex metabolic and regulatory networks for systems wide re-
direction of pathway flux to support production. This seems particularly important 
for violacein and deoxyviolacein biosynthesis, embedded into the interconnected 
network of carbon core metabolism and tightly constrained by different layers of 
metabolic (Zhang et al., 2010) and transcriptional regulation (Landick et al., 1985; 
McClean et al., 1997).  
In this regard, the present work describes systems metabolic engineering of 
E. coli for production of violacein and deoxyviolacein. Initially, an analytical method 
to quantify the content of violacein and deoxyviolacein with high precision in a 
single analysis was developed. Afterwards, E. coli was recruited due to its high 
capability to produce L-tryptophan (Balderas-Hernández et al., 2009; Ikeda, 2006), 
the building block for the desired pigments. Starting from a basic producer that 
expressed the vioABCE genes from Chromobacterium violaceum, E. coli was 
stepwise improved for overproduction of deoxyviolacein. Based on careful 
analysis, the central metabolism of E. coli was globally optimized, which involved 
engineering of (i) the pentose phosphate pathway, (ii) the entire biosynthesis up to 
the level of the chorismate and (iii) the tryptophan route, (iv) enhanced supply of 
serine, (v) elimination of tryptophan repression/attenuation and (vi) degradation 
(tryptophanase). The deoxyviolacein producer E. coli dVio-6 comprised these 
genomic traits together with plasmid-based expression of vioABCE under control 
of the araBAD promoter system, inducible by L-arabinose. The mutant 
accumulated 320 mg L-1 deoxyviolacein, whereby the araBAD system mediated a 
precisely controllable induction of vioABCE. The titer was markedly higher than 
that achieved in previous approaches, but still left space for further improvement. 
Particularly, L-arabinose had to be used as source of carbon, as E. coli is able to 
metabolize this sugar (Desai and Rao, 2010; Englesberg et al., 1965), which 
enabled only slow growth and resulted in unfavorable long process times. 
Moreover, L-arabinose was required in large amounts, limiting economic success 
due to high price of L-arabinose, about hundred-fold higher than that of traditional 
biotechnology sugars. Accordingly, the next-generation strain able to use 
alternative raw materials was constructed. Strain engineering involved elimination 
of L-arabinose catabolism, while L-arabinose uptake encoded by araE and araFGH 
was retained. Isotope experiments with 13C L-arabinose verified that L-arabinose 
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was still taken up and served as inducer of vioABCE expression, but was no 
longer metabolized by the created mutant. Out of different raw materials tested, 
glycerol was identified as promising carbon source for production. In a glycerol-
based fed-batch process the novel mutant produced 1.6 g L-1 of deoxyviolacein, 
which is five-fold higher than previously achieved and provides an attractive option 
to derive this valuable drug from cheap raw materials. Afterwards, by integration of 
the vioD gene into the chromosome, the E. coli with optimized metabolism for high 
tryptophan production was additionally modified into a violacein producer. In all 
cases, the desired compound could be obtained as exclusive product using L-
arabinose as carbon source. Subsequently, the performance of the engineered 
overproducer was assessed in a fed-batch process, yielding about 700 mg L-1 of 
pure violacein.  
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2 Materials and Methods 
2.1. Development of methods for separation and 
quantification of violacein and deoxyviolacein 
2.1.1. Organisms and growth conditions 
Recombinant Escherichia coli TOP10 (Invitrogen), harboring  the  violacein 
operon from Chromobacterium violaceum on pBvioABCDE (Rodrigues et al., 
2013), on pJP1000 or on pPSX-Vio+ (Sarovich and Pemberton, 2007) and the 
natural producer Janthinobacterium lividum DSM 1522 (Pantanella et al., 2007), 
obtained from the DSMZ (Braunschweig, Germany),  were used for production. 
Liquid cultures were performed in shake flasks at 25 °C on LB medium with 10 g L-
1 L-arabinose (E. coli) or with 10 g L-1 glycerol (J. lividum). In addition, plate 
cultures were grown on LB agar at 20 °C until pigmented colonies were obtained. 
For pigment extraction, cells were collected by centrifugation (4650×g, 15 min, 4 
°C, Multifuge 4KR, Heraeus, Hanau, Germany) either from the broth of a liquid 
culture or from a colony suspension of a plate culture in deionized water. 
Subsequently, violacein and deoxyviolacein were extracted from the cells with 
ethanol (Mendes et al., 2001). 
2.1.2. Preparation of pure violacein and deoxyviolacein 
Pure deoxyviolacein was prepared from ethanol extracts of E. coli TOP10 
pBvioABCDE. The obtained ethanol extract was separated from the cells by 
centrifugation and then concentrated at reduced pressure (Laborota 4000, 
Schwabach, Germany). The concentrated extract was purified by flash-
chromatography using silica gel 60 (0.040-0.063 mm, Merck, Darmstadt, 
Germany) and 70% (v v-1) ethanol as mobile phase. The violet fraction containing 
deoxyviolacein was collected, concentrated under reduced pressure and dried. 
Analysis by 1H and 13C NMR spectroscopy (Wille and Steglich, 2001) and HR-ESI-
MS ([M+H]+: calc. 328.10805, found 328.10782) confirmed the identity and purity 
of deoxyviolacein without any detectable amounts of violacein (This analysis was 
performed at the Institute of Organic Chemistry, Technische Universität 
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Braunschweig by the work group of Prof. Dickschat). Similarly, a violacein 
standard from cultures of E. coli TOP10 pPSX-Vio+ was obtained.  
2.1.3. Quantification of violacein and deoxyviolacein 
Samples were analyzed by HPLC (LaChrom Elite, Hitachi High-
Technologies Corporation, Mannheim, Germany) with a C18 column (Thermo 
Scientific, Hypersil ODS, 5 µm, 250×4.6 mm) at 30 °C. Different concentrations of 
methanol and ethanol were tested as mobile phase at a flow rate of 0.5 mL min-1. 
The injection volume was 10 µl. The detection was based on a diode array 
detector with signal monitoring between 200-700 nm. Violacein and deoxyviolacein 
were quantified on basis of external standards.  
2.1.4. Estimation of extinction coefficients 
A spectrophotometer Libra S11 (Biochrom, Cambridge, UK) was used for 
determination of the extinction coefficients of violacein and deoxyviolacein 
dissolved in ethanol solutions at different ratios. 
2.2. Systems metabolic engineering of Escherichia coli for 
production of violacein and deoxyviolacein from L-
arabinose 
2.2.1. Strains and plasmids 
Escherichia coli K-12 MG1655 (Jensen, 1993) (CGSC 6300) was used as 
host for heterologous production. Its derivative, E. coli BW25113 (Datsenko and 
Wanner, 2000) was used for chromosomal integration cloning, as given in the 
Supplementary Information. E. coli DH10B (Life GmbH, Darmstadt, Germany) was 
used for standard cloning and plasmid maintenance. The vioABCDE operon that 
encoded the violacein biosynthetic pathway was derived from genomic DNA of 
Chromobacterium violaceum ATCC 12472 (American Type and Culture Collection, 
Manassas, USA). The vioD gene was cloned from Janthinobacterium lividum DSM 
1522 (Leibniz Institute DSMZ - German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany). The plasmid pBADMycHisB was used for 
heterologous expression of the vio operon in E. coli (Life GmbH, Darmstadt, 
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Germany). This plasmid contains the bla gene for ampicillin resistance and the L-
arabinose inducible PBAD promoter upstream of the multiple cloning site. The 
plasmids pKD3, pKD4, pKD46 (Datsenko and Wanner, 2000), pClik5a (Krömer et 
al., 2006) and pCP20 (Cherepanov and Wackernagel, 1995) were used to perform 
genetic modifications in E. coli K-12 MG1655. Chaperone expressing plasmids 
pGro7, pG-KJE8, pKJE7, pG-Tf2, and pTf16 were purchased from Takara Bio, 
Inc., Japan. The plasmid pJNNmod (see Appendix) was used for cloning of the 
vioD gene from J. lividum. All plasmids and strains used are listed in Table 2. 
Generally, molecular biology procedures followed standard protocols (Sambrook 
and Russell, 2001). Gene deletion and genomic modification of E. coli was 
performed by recombineering (Datsenko and Wanner, 2000) using specific primer 
pairs as indicated (Table 3). All strains were maintained as glycerol stocks at -80 
°C. 
2.2.2. Construction of the violacein production plasmid  
First, the vioABCD genes of C. violaceum ATCC 12472 were amplified from 
genomic DNA by nested PCR (Mastercycler Gradient Thermal Cycler, Eppendorf, 
Hamburg, Germany) with external (1, 2) and internal primers (3, 4) as given in 
Table 3. The plasmid pBvioABCD was then constructed by insertion of the 
vioABCD genes into the multiple cloning site. The vioE gene was amplified from 
genomic DNA of C. violaceum ATCC 12472 using the primers 5 and 6 (Table 3). 
The plasmid pBvioABCDE was obtained by subsequent insertion of the vioE gene 
downstream of vioD into the plasmid pBvioABCD. The correct insertion of the 
heterologous vio genes was verified by sequencing (Macrogen, Korea). 
 
Table 2. Strains and plasmids. 
Strains and 
plasmids 
Relevant genotype Reference 
Strains   
E. coli   
 DH10B ∆(ara,leu)7697 araD139 
(Life GmbH, 
Darmstadt, 
Germany) 
 
BW25113 
(CGSC#: 
MG1655 lacI
q
 rrnBT14 ∆lacZWJ16 hsdR514 ∆araBADAH33 
∆rhaBADLD78 
(Datsenko 
and Wanner, 
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7636) 2000) 
 
MG1655 
(CGSC#: 
6300) 
Wild type E. coli K-12 
(Jensen, 
1993) 
 TRP1 BW25113 ∆sdaA::FRT-Cm-FRT 
see 
Appendix. 
 TRP2 BW25113 ∆trpE::FRT-Km-FRT 
see 
Appendix. 
 TRP3 BW25113 ∆trpL trpE
fr 
 
see 
Appendix. 
 TRP4 F52 ∆lac::PTACaroFBL-FRT-Km-FRT 
see 
Appendix. 
 TRP5 BW25113 Ara+ ∆tktA ∆gal::PTACtktA-FRT-Cm-FRT 
see 
Appendix. 
 TRP6 BW25113 ∆serA ∆xyl::PTACserA
fr
-FRT-Km-FRT 
see 
Appendix. 
 TRP7 MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT-Cm-FRT This study 
 TRP8 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT-Cm-FRT ∆trpL 
trpE
fr
 
This study 
 TRP9 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
lac::PTACaroFBL-FRT ∆trpL trpE
fr
 
This study 
 TRP10 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT-Cm-FRT 
This study 
 TRP11 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT 
This study 
 NC MG1655 pBADMycHisB-Km This study 
 dVio-1 MG1655 pBvioABCE-Km This study 
 dVio-2 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT-Cm-FRT 
pBvioABCE-Km 
This study 
 dVio-3 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT-Cm-FRT ∆trpL 
trpE
fr
 pBvioABCE-Km 
This study 
 dVio-4 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 pBvioABCE-Km 
This study 
 dVio-5 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT-Cm-FRT 
pBvioABCE-Km 
This study 
 dVio-6 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
This study 
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∆xyl::PTACserA
fr
-FRT pBvioABCE-Km 
 Vio-1 BW25113 ∆fuc:: PTACvioD-FRT-Km-FRT This study 
 Vio-2 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT ∆fuc:: PTACvioD-FRT-Km-FRT 
This study 
 Vio-3 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT ∆fuc:: PTACvioD-FRT 
This study 
 Vio-4 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT ∆fuc:: PTACvioD-FRT pBvioABCE-Km 
This study 
Chromobacterium 
violaceum  
  
 ATCC 12472 vioABCDE 
(de 
Vasconcelos 
et al., 2003) 
Janthinobacterium 
lividum 
  
 DSM 1522 vioD 
(Kimmel and 
Maier, 1969) 
    
Plasmids   
 pG-KJE8 dnaK-dnaJ-grpE-groES-groEL, araB, Pzt-l 
Takara Bio 
Inc., Japan 
 pGro7 groES-groEL, araB 
Takara Bio 
Inc., Japan 
 pKJE7 dnaK-dnaJ-grpE, araB 
Takara Bio 
Inc., Japan 
 pG-Tf2 groES-groEL-tig, Pzt-l 
Takara Bio 
Inc., Japan 
 pTf16 tig, araB 
Takara Bio 
Inc., Japan 
 
pBADMycHis
B 
PBAD bla 
(Life GmbH, 
Darmstadt, 
Germany) 
 
pBADMycHis
B-Km 
PBAD bla Km This study 
 pKD3 Cm  
(Datsenko 
and Wanner, 
2000) 
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 pKD4 Km 
(Datsenko 
and Wanner, 
2000) 
 pKD46 PBADgam-bet-exo  
(Datsenko 
and Wanner, 
2000) 
 pCP20 FLP 
(Cherepanov 
and 
Wackernagel
, 1995) 
 pClik5a Km 
(Krömer et 
al., 2006) 
 pBvioABCD vioABCD This study 
 pBvioABCDE vioABCDE This study 
 
pBvioABCDE-
Km 
vioABCDE Km This study 
 
pBvioABCE-
Km 
vioABCE Km This study 
 pJNNmod PTAC, lacI
q
, ColE1 origin of replication 
see 
Appendix. 
 
pJNNmod+vio
D 
PTACvioD This study 
 
pJNNmod+vio
D-Km 
PTACvioD-FRT-Km-FRT This study 
 
The aphA gene for kanamycin resistance (Km) was amplified from plasmid pKD4 
using the primers 7 and 8 for insertion into the plasmid pBvioABCDE. The 
obtained PCR product was digested with DpnI to degrade the template DNA. The 
amplicon containing the Km (aphA gene) was isolated and purified by agarose gel 
electrophoresis and was then cloned into pBvioABCDE yielding the plasmid 
pBvioABCDE-Km. The obtained plasmid was then transformed in E. coli using 
standard protocols (Sambrook and Russell, 2001). 
2.2.3. Construction of the deoxyviolacein production plasmid 
In order to remove the vioD gene from pBvioABCDE-Km, the upstream and 
downstream regions of this gene were amplified by PCR using the primer pairs 9, 
10 and 11, 12, respectively (Table 3). The PCR products were isolated by agarose 
gel electrophoresis and applied to overlapping extension PCR using primers 9 and 
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12 (Table 3). The PCR product was used to replace the vioD gene by the 
shortened fragment yielding the plasmid pBvioABCE-Km. The construct was 
validated by PCR. 
2.2.4. Genomic integration of the vioD gene  
The vioD gene was amplified from J. lividum DSM 1522 using primers 23 
and 24 (Table 3). The amplicon containing the vioD ORF was isolated by agarose 
gel electrophoresis, digested with NdeI and HindIII and cloned into pJNNmod 
previously digested with the same restriction enzymes. The construct was 
sequenced (GATC Biotech AG, Konstanz, Germany) to ensure proper 
replacement of the native promoter of the vioD gene by the PTAC promoter. The Km 
from pKD4 was subsequently inserted as resistance marker. Finally, the PTACvioD-
FRT-Km-FRT construct was inserted into the fucPIK locus of E. coli BW25113 
using primers 25 and 26 (Albermann et al., 2010) (Table 3). 
2.2.5. Transduction of target constructs 
The strains TRP1 through TRP3, TRP5, TRP6 (Table 2 and Supplementary 
Information), and Vio-1 (Table 2) are derivatives of strain BW25113 and were used 
as sources of the following gene constructs: ∆sdaA::FRT-Cm-FRT; ∆trpE::Km; 
 
Table 3. Primers used for genetic construction work. 
Primer ID Primers (5’->3’) Target 
1 acgaaaggcagcatcccgattcc 
Amplification of vioABCD  
in C. violaceum ATCC 
12472 
2 gcgctcgtagtcgaaccagcagtag 
3 aggacattctcgaggaagcattcttccgatatctg 
4 actccggtaccacacataggcgctgctc 
   
5 gcgctggtacctgcaacgctgaggag Amplification of vioE in  
C. violaceum ATCC 12472 6 cgaaaggtaccccgtttttctgcccgat 
   
7 gtggccagtgccaagcttgcatgc Amplification of Km in pKD4 
for  
eventual insertion into 
pBvioABCDE, 
pBADMycHisB, and 
pJNNmod+vioD 
8 ggcaagcttaacggctgacatgggaattag 
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9 ggcgcgcgccaactacgacgtgctca 
Deletion of vioD in 
pBvioABCDE-Km 
10 gcgttgcagcgcgtagcgcacagaatcttcatcagttgac 
11 gtcaactgatgaagattctgtgcgctacgcgctgcaacgc 
12 cgtagtcgaaccagcagtagccggacgtca 
   
13 tttatgatatgctatcgtactctttagcgagtacaaccgggggagggaag
ttcctatactttctagagaataggaacttccacgcgtcatatgactagtt Amplification of Km in  
pClik5a for trpR deletion  
in E. coli K-12 MG1655  
14 tcggtgcacgatgcctgatgcgccacgtcttatcaggcctacaaaaga
agttcctattctctagaaagtataggaacttccagcgagtcagtgagcg
agg 
   
15 tttatgatatgctatcgtactctttagcgagtacaaccgggggagggtgta
ggctggagctgcttc 
Amplification of Cm in pKD3 
for Km deletion in E. coli  
K-12 MG1655 ΔtrpR-FRT-
Km-FRT 
16 tcggtgcacgatgcctgatgcgccacgtcttatcaggcctacaaaaatg
ggaattagccatggtcc 
   
17 caattgctggatccggaaacgaatatcaac Amplification of trpR of E. 
coli 
K-12 MG1655 to check for 
trpR deletion 
18 cgctgagtccgtttcataatgccgtgtat 
   
19 gcatatatatctggcgaattaatcggtatagcagatgtaatattcacagg
gtgtaggctggagctgcttc 
Amplification of Cm in pKD3 
for tnaA deletion in E. coli 
K-12 MG1655 ΔtrpR-FRT 
20 tgtagggtaagagagtggctaacatccttatagccactctgtagtattaa
atgggaattagccatggtcc 
   
21 catcaccagagccaaaccgattagattcaa Amplification of tnaA in E. 
coli  
K-12 MG1655 ΔtrpR-FRT to 
check  
for tnaA deletion 
22 cgctgataatgttccaggtgttaccgat 
   
23 taaacatatgaaaattctcgtcatcggcgcagg Amplification of vioD in J. 
lividum DSM 1522 for 
insertion into pJNNmod 
24 ggtaaagcttttagcggcccagcgcgta 
   
25 tgctgtgctcactgttttttctttgggcggtagccaataaccttaacgacattt
tattatcaaggcgcactcccgttctgg 
Amplification of PTACvioD-
FRT-Km-FRT in 
pJNNmod+vioD-Km for 
insertion into  
E. coli BW25113 
26 cagcatggaggcgagagtgataaagtctgcgccaacgtggccgatg
gtcagaacccccagggttattgtctcatgagcg 
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∆trpL, trpEfr; ∆gal::PTACtktA-FRT-Cm-FRT; ∆xyl::PTACserA
fr-FRT-Km- FRT; and 
∆fuc::PTACvioD-FRT-Km-FRT, respectively. Strain TRP4, a W3110 derivative 
(Supplementary Information), was the ultimate source of the construct 
∆lac::PTACaroFBL-FRT-Km-FRT.  Recombinant E. coli strains were obtained by 
transferring these genes among the strains by transduction using phage P1vir, 
following a previously described method (Thomason et al., 2007).  
2.2.6. Growth media  
LB medium was composed of 10 g L-1 NaCl, 5 g L-1 yeast extract (Difco, 
Detroit, USA), and 10 g L-1 tryptone (Difco, Detroit, USA) at pH 7. For strains 
harboring plasmids that had been derived from pBADMycHisB, the medium was 
additionally amended with 100 µg mL-1 ampicillin, except for strains containing 
pBvioABCE-Km that received either 100 µg mL-1 ampicillin or 50 µg mL-1 
kanamycin. In case of strains that contained chaperone-expression plasmids, the 
medium was supplemented with 20 μg mL-1 chloramphenicol. Tetracycline (5 ng 
mL-1) was used for induction of gene expression in plasmids pG-Tf2 and pG-KJE8. 
For evaluation of production performance on plates, the LB medium was 
supplemented with 1 g L-1 L-arabinose for induction and solidified by addition of 15 
g L-1 agar. Medium sterilization was carried out by autoclaving. L-Arabinose and 
antibiotic stock solutions were filter-sterilized (0.22 μm, Sartorius Stedim Biotech, 
Germany) and added to the medium at room temperature. The mineral medium 
used for production was modified from (Al Zaid Siddiquee et al., 2004) and 
contained per liter of deionized water: 0.58 g NaCl, 5.29 g (NH4)2SO4, 17.41 g 
K2HPO4, 13.61 g KH2PO4, 0.25 g MgSO4 7H2O, 1 μg thiamin HCl, 3 mg vitamin 
B3, 1 mg vitamin B2, 5.51 mg CaCl2, 16.66 mg FeCl3 6H2O, 1 mg MnCl2 4H2O, 1.7 
mg ZnCl2, 340 μg CuCl2, 470 μg CoCl2 and 600 μg Na2MoO4 2H2O. The pH was 
adjusted to 7.8 with 4 M NaOH. The vitamin solutions were filter-sterilized (0.22 
μm, Sartorius Stedim Biotech, Germany). The remaining components were 
sterilized by autoclaving, cooled to room temperature and mixed together before 
use. For pre-cultivation and production of the pigments, 10 g L-1 glucose and 10 g 
L-1 L-arabinose were used as carbon source, respectively. Hereby the glucose 
stock solution (10x) used was sterilized by autoclaving, whereas the L-arabinose 
stock (20x) solution was sterilized by filtration (Minisart, 0.2 µm, 28 mm, Sartorius, 
Göttingen, Germany). The medium used for pre-cultivation in shake-flasks and for 
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the batch-phase of the bioreactor cultivations was a modification of the mineral 
medium described above, in which the concentration of K2HPO4 and KH2PO4 were 
changed to 12.542 g L-1 and 2.313 g L-1, respectively. In addition, 12 g L-1 tryptone 
(Difco, Detroit, USA) and 24 g L-1 yeast extract (Difco, Detroit, USA) were added. 
For pre-cultivation and production of the pigments in bioreactor, 10 g L-1 glucose 
and 10 g L-1 L-arabinose were added to each medium, respectively. The medium 
used for the fed-batch phase was composed of 21.4 g L-1 MgSO4 7H2O, 50 mg L
-1 
kanamycin and 360 g L-1 L-arabinose. The medium was sterilized by filtration 
(Sartolab-P20 plus, 0.2 µm, Sartorius, Göttingen, Germany). Antifoam agent 
(Ucolub N115, Fragol Industrieschmierstoffe, Germany) was manually added in 
pulses of 30 µL, when necessary. 
2.2.7. Cultivation in shake flasks  
Glycerol stocks were used as inoculum for pre-cultures in mineral medium, 
which were incubated for 18 h at 37 °C. Cells obtained from pre-cultures were 
washed two times by centrifugation (5 min, 9800×g, 20 °C, Biofuge Stratos, 
Heraeus, Hanau, Germany). After re-suspension in 0.85% (w v-1) NaCl solution, 
they were used as inoculum for the main cultures. All cultivations were performed 
in baffled shake flasks with 10% filling volume and incubated on an orbital shaker 
at 230 rpm. Different incubation temperatures were applied, as specified below. 
For on-line dissolved oxygen quantification, shake flasks were equipped with non-
invasive oxygen sensors (PreSens, Regensburg, Germany) and connected to a 4-
channel fiber optic oxygen transmitter (OXY-4, PreSens, Regensburg, Germany) 
as described previously (Wittmann et al., 2003).  
2.2.8. Fed-batch production in bioreactor 
Exponentially growing cells from pre-cultures were collected by 
centrifugation (5 min, 10016×g, 20 °C, Biofuge Stratos, Heraeus, Hanau, 
Germany), washed with culture medium and used as inoculum. A lab scale (700 
mL) DASGIP bioreactor system (Jülich, Germany) was used for production of 
violacein by the recombinant E. coli Vio-4. The initial settings of the process 
included a temperature of 20 °C, aeration rate of 6.0 sL h-1, and stirrer speed of 
400 rpm. Dissolved oxygen was measured by an optic sensor (Hamilton, Höchst, 
Germany) which was set to 30% by controlling the stirring speed. The pH was 
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maintained at 7.8 by addition of 1 M HCl or 25% NH4OH. During later stages of the 
process, exponential feeding was applied as given by Equation 1.  
sx
μt
0
YS
eVμX
=F
/0
0  (1) 
Hereby, F, μ, X0, V0, t, S0 and Yx/s denote the feed rate, specific growth rate, initial 
cell concentration, initial medium volume, time, substrate concentration in the feed 
medium and the biomass yield on substrate, respectively (Yee and Blanch, 1992). 
The parameters (µmax = 0.0182 h
-1, Yx/s = 0.235 g g
-1) were determined based on 
the results obtained from the cultivations of strain dVio-6 in mineral medium with L-
arabinose. The addition of the feed medium was controlled by a REGLO Digital 
MS-2/12 pump (Ismatec, Glattbrugg, Switzerland). 
2.2.9. Quantification of cell concentration  
Cell dry weight (CDW) was determined gravimetrically. Culture broth was 
filtered on pre-dried and pre-weighted filters (cellulose acetate, 0.2 µm, 25 mm, 
Sartorius, Göttingen, Germany). The filters were dried until constant weight, 
cooled in a desiccator to room temperature and then used for gravimetric biomass 
quantification (Analytical balance BP 210D, Sartorius, Göttingen, Germany). In 
addition, the cell concentration was also quantified via measurement of the optical 
density at 600 nm. This yielded a correlation factor of 1 OD600 = 0.221 (g CDW) L
-1.  
2.2.10. Quantification of violacein and deoxyviolacein  
For extraction of the products, 600 µL culture broth was mixed thoroughly 
with 1.2 mL ethyl acetate and 175 mg glass beads (0.5 mm diameter). The cells 
were separated by centrifugation (3 min, 9800×g, 20 °C, Biofuge Stratos, Heraeus, 
Hanau, Germany) and subjected to repeated extraction until no more pigment 
color accumulated in the organic phase. All ethyl acetate extracts were pooled and 
dried at 20 °C. The obtained pigments were re-dissolved in ethanol. Violacein and 
deoxyviolacein were then quantified in these solutions by HPLC as described 
previously (Rodrigues et al., 2012). 
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2.2.11. Quantification of sugars and organic acids  
Culture samples were centrifuged (3 min, 9800×g, 20 °C, Biofuge Stratos, 
Heraeus, Hanau, Germany), filtered (cellulose acetate, 0.2 µm, 25 mm, Sartorius, 
Göttingen, Germany) and analyzed for organic acids (Becker et al., 2009a) and 
sugars (Buschke et al., 2011) by HPLC (LaChromElite, Hitachi, VWR, Darmstadt, 
Germany). Separation of organic acids was performed on a reversed phase 
column (Aminex HPX 87H, 300×78 mm, Bio-Rad, Hercules, California) with 12.5 
mM H2SO4 as mobile phase at a flow rate of 0.5 mL min
-1 and 45 °C. 
Quantification was carried out via external calibration and UV detection at 210 nm. 
Glucose and L-arabinose were separated on a Metacarb 87C column (300 × 78 
mm, Varian Inc., Palo Alto, USA) at 85 °C with purified water (Milli-Q Gradient A10 
Water Purification System, Millipore, Schwalbach am Taunus, Germany) as mobile 
phase, flow rate of 0.6 mL min-1 and quantified via the refraction index after 
external calibration. 
2.2.12. Intracellular amino acids  
Sampling was performed using fast filtration and washing with isotonic NaCl 
solution, a method that had been validated for accurate quantification of 
intracellular metabolites in E. coli (Bolten et al., 2007). Samples of exponentially 
growing cultures were harvested by fast filtration (cellulose acetate filter, 0.2 µm, 
25 mm, Sartorius, Göttingen, Germany) and washed with 31.4 g L-1 NaCl solution 
that equaled the ionic strength of the mineral medium. In order to extract the 
intracellular amino acids, the filters were incubated for 15 min at 100 °C in 2 mL 
boiling water, which contained the internal standard 200 µM α-aminobutyrate, and 
then cooled on ice. Extracts were recovered after centrifugation (3 min, 9800×g, 4 
°C, Biofuge Stratos, Heraeus, Hanau, Germany) and used for quantification by 
HPLC (Agilent 1200, Agilent, Waldbronn, Germany) with a reverse phase column 
(Gemini 5 µm C18 110 Å, 150×4.6 mm, Phenomenex, Aschaffenburg, Germany) 
(Krömer et al., 2005). Before injection, the amino acids were derivatized with o-
phthaldialdehyde and detected by fluorescence with excitation at 340 nm and 
emission at 540 nm (Agilent, Waldbronn, Germany). 
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2.2.13. Extraction and crystallization of violacein  
Cells were collected by centrifugation (5 min, 10016 × g, 20 °C, Biofuge 
Stratos, Heraeus, Hanau, Germany). Violacein was then extracted by mixing the 
cells with ethanol followed by separation of the violacein extract (5 min, 10016 × g, 
20 °C, Biofuge Stratos, Heraeus, Hanau, Germany). This procedure was repeated 
until violacein was completely extracted from the cells. The obtained extract was 
filtered (Rapid 250, 0.22 µm PES membrane, TPP Techno Plastic Products AG, 
Trasadingen, Switzerland), dried at reduced pressure (Laborota 4000, 
Schwabach, Germany) and solubilized in boiling acetone (Wrede and Rothhaas, 
1933). One volume of purified water (Milli-Q Gradient A10 Water Purification 
System, Millipore, Schwalbach am Taunus, Germany) at 100 °C was added to the 
boiling acetone-violacein extract. Subsequently, crystallization of violacein was 
carried out by incubation at 20 °C for 24 h. Crystal formation was evaluated by 
microscopy (EVOS xl, Advanced Microscopy Group, Bothell, USA). Finally, the 
crystals were recovered by filtration (0.2 µm regenerated cellulose membrane, 
Sartorius Stedim Biotech, Germany), washed with purified water, dried at 80 °C 
until constant weight and stored at 0 °C. The purity of violacein crystals was 
evaluated by HPLC as described above. Violacein crystals were solubilized in 
ethanol prior to analysis. 
 
2.3. Systems metabolic engineering of Escherichia coli for 
production of deoxyviolacein from glycerol 
2.3.1. Strains and plasmids 
The araBAD operon, encoding enzymes of L-arabinose catabolism, was 
deleted in E. coli K-12 MG1655 (Jensen, 1993) (CGSC 6300) for later transduction 
of the obtained ∆araBAD::FRT-Cm-FRT construct into deoxyviolacein producing 
strains. E. coli dVio-6 and E. coli TRP11 were taken from previous work 
(Rodrigues et al., 2013). The pBvioABCE-Km plasmid (Rodrigues et al., 2013), 
encoding the biosynthetic pathway of deoxyviolacein, was employed for production 
of deoxyviolacein with L-arabinose as inducer of gene expression. Plasmids pKD3 
and pKD46 (Datsenko and Wanner, 2000) were used to perform genetic 
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modifications in E. coli K-12 MG1655. All strains were maintained as glycerol 
stocks at -80 °C. All strains and plasmids, used in the present work, are 
summarized in Table 4. 
 
Table 4. Strains and plasmids used in the present work. 
 Relevant genotype Reference 
Strains   
E. coli   
 
MG1655 
(CGSC#: 
6300) 
Wild type E. coli K-12 
(Jensen, 
1993) 
 ∆araBAD MG1655 ∆araBAD::FRT-Cm-FRT  This study 
 TRP11 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT 
(Rodrigues 
et al., 2013) 
 dVio-6 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT pBvioABCE-Km 
(Rodrigues 
et al., 2013) 
 dVio-7 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT ∆araBAD::FRT-Cm-FRT 
This study 
 dVio-8 
MG1655 ∆trpR::FRT ∆tnaA::FRT ∆sdaA::FRT 
∆lac::PTACaroFBL-FRT ∆trpL trpE
fr
 ∆gal::PTACtktA-FRT 
∆xyl::PTACserA
fr
-FRT ∆araBAD::FRT-Cm-FRT pBvioABCE-Km 
This study 
Plasmids   
 pKD3 Cm 
(Datsenko 
and Wanner, 
2000) 
 pKD46 PBADgam-bet-exo  
(Datsenko 
and Wanner, 
2000) 
 
pBvioABCE-
Km 
vioABCE Km Amp 
(Rodrigues 
et al., 2013) 
 
2.3.2. Genetic engineering 
The recombineering method (Datsenko and Wanner, 2000) was used to 
delete genes in E. coli. The chloramphenicol resistance gene of pKD3 plasmid 
was taken as selection marker. Specific primers for implementation and validation 
of genetic modifications are listed in Table 5. Transfer of genetic constructs among 
strains was performed with transduction (Thomason et al., 2007), using the phage 
Material and Methods 
 
 45 
P1vir. For heterologous production of deoxyviolacein, plasmid pBvioABCE-Km 
was transferred into E. coli (Sambrook and Russell, 2001). 
 
Table 5. Primers used for deletion of araBAD in E. coli. 
No. Primers (5’→3’) Target 
1 
atggcgattgcaattggcctcgattttggcagtgattctgtgcgagctttgtgta
ggctggagctgcttc 
Cm of pKD3 
2 
gcttgagtatagcctggtttcgtttgattggctgtggttttatacagtcaatggga
attagccatggtcc 
   
3 atatcacccggtcggcagacaaattctcgt validating deletion of 
araBAD in E. coli K-12 
MG1655 ∆araBAD 
4 aatatgctgagcgcggggaacctga 
   
5 caattgctggatccggaaacgaatatcaac 
validating deletion of trpR 
6 cgctgagtccgtttcataatgccgtgtat 
 
2.3.3. Growth media 
Complex LB medium (pH 7) contained 10 g L-1 NaCl, 5 g L-1 yeast extract 
(Difco, Detroit, MI, USA), and 10 g L-1 tryptone (Difco, Detroit, MI, USA). For 
strains, that harbored the deoxyviolacein plasmid (pBvioABCE-Km), it was 
additionally amended with either 100 µg mL-1 carbenicillin or with 50 µg mL-1 
kanamycin, respectively. For evaluation of production performance on plates, LB 
medium was further supplemented with 1 g L-1 L-arabinose for induction and 
solidified by addition of 15 g L-1 agar. Mineral medium (Rodrigues et al., 2013) 
contained per liter of deionized water: 0.58 g NaCl, 5.29 g (NH4)2SO4, 12.542 g 
K2HPO4, 2.313 g KH2PO4, 0.25 g MgSO4 × 7H2O, 1 μg thiamin HCl, 3 mg vitamin 
B3, 1 mg vitamin B2, 5.51 mg CaCl2, 16.66 mg FeCl3 × 6H2O, 1 mg MnCl2 × 
4H2O, 1.7 mg ZnCl2, 340 μg CuCl2, 470 μg CoCl2 and 600 μg Na2MoO4 × 2H2O at 
pH 7. For strains, that harbored the deoxyviolacein plasmid (pBvioABCE-Km), the 
medium was additionally amended with either 100 µg mL-1 carbenicillin or with 50 
µg mL-1 kanamycin. Media for cultivation of strains, harboring the construct 
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∆araBAD::FRT-Cm-FRT, were supplemented with 20 µg mL-1 chloramphenicol, 
except for bioreactor cultivations. Cultivation in microplates was conducted in 
mineral medium (see above), which was additionally amended with 3 g L-1 
tryptone (Difco, Detroit, MI, USA), 6 g L-1 yeast extract (Difco, Detroit, MI, USA), 
and 100 µg mL-1 carbenicillin. Either 10 g L-1 glycerol or 10 g L-1 fructose were 
added as extra carbon source. L-Arabinose concentrations between 10 and 500 
mg L-1 were tested for induction of gene expression. L-Arabinose-based medium 
and feed solution, used for fed-batch production with E. coli dVio-6, were as 
described previously (Rodrigues et al., 2013). Additionally, novel media were 
developed for fed-batch production with alternative carbon sources in this work. 
For the initial batch phase, mineral medium, as described above, was 
supplemented with 10 g L-1 glucose and with 100 µg mL-1 carbenicillin. 
Subsequently, a variant of this medium was added, in which glucose was replaced 
by 10 g L-1 glycerol and additionally 6 g L-1 tryptone (Difco, Detroit, MI, USA), 12 g 
L-1 yeast extract (Difco, Detroit, MI, USA), 6 g L-1 L-arabinose, and 100 µg mL-1 
carbenicillin. The feed-solution contained 21.4 g L-1 MgSO4 × 7H2O and 756.6 g L
-
1 glycerol. Antifoam agent (Ucolub N115, Fragol Industrieschmierstoffe, Germany) 
was manually added to bioreactor cultivations, when necessary.  
 
2.3.4. Microplate cultivation 
Glycerol stocks were used as inoculum for pre-cultivation in mineral 
medium with glucose. Baffled flasks (500 mL) with 50 mL medium were incubated 
for 17 h at 37 °C and 230 rpm on an orbital shaker (Multitron, Infors AG, 
Bottmingen, Switzerland). Cells were collected by centrifugation (5 min, 9800 × g, 
20 °C). After re-suspension in mineral medium, cells were used as inoculum for 
the microplate cultivations. Parallel cultivation in 48-well microtiter flower-plates 
was conducted with the BioLector system (DASGIP, Jülich, Germany). Cultivations 
were performed at 20 °C, 95% humidity, and 1000 rpm. Each well was filled with 1 
mL medium. Cell growth was determined by online monitoring of optical density at 
620 nm. 
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2.3.5. Shake flask cultivation 
Pre-cultivations were done as described above. Dissolved oxygen level in 
shake-flask cultures was quantified with the shake-flask reader SFR (PreSens 
Precision Sensing GmbH, Regensburg, Germany). Cultures (500 mL flasks with 
50 mL medium) were incubated at 37 °C and 230 rpm on an orbital shaker 
(Multitron, Infors AG, Bottmingen, Switzerland). 
 
2.3.6. Fed-batch cultivation 
A lab scale bioreactor system (DASGIP, Jülich, Germany) was used for 
production of deoxyviolacein. Initial settings of the fed-batch experiment with strain 
dVio-6 were as described previously (Rodrigues et al., 2013). Initial settings of the 
fed-batch with strain dVio-8, developed in this work, were 37 °C, an aeration rate 
of 6.0 sL h-1, a cell concentration of OD600 of 1, a stirrer speed of 400 rpm, and a 
filling volume of 300 mL medium. Dissolved oxygen was measured by an optical 
sensor (Hamilton, Höchst, Germany) and kept above 30% by automatic 
adjustment of stirrer speed. The pH was maintained at 7 by addition of 3 M HCl 
and 25% NH4OH, respectively. After initial glucose was consumed, modified batch 
medium was added and the reactor was cooled down to 20 °C. When the 
dissolved oxygen level had reached 60%, the feed was started. Medium addition 
was then performed in pulses of 5 g L-1 glycerol, each time the dissolved oxygen 
level increased to values above 60%. Addition of feed medium was conducted by 
a REGLO Digital MS-2/12 pump (Ismatec, Glattbrugg, Switzerland). 
 
2.3.7. Quantification of cell concentration 
A spectrophotometer (Libra S11, Biochrom, Cambridge, UK) was used for 
determination of cell concentration via measurement of optical density at 600 nm 
(Rodrigues et al., 2013). 
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2.3.8. Quantification of sugars, glycerol and acetate 
Culture samples were centrifuged (3 min, 9800×g, 20 °C), filtered (cellulose 
acetate, 0.2 µm, 25 mm, Sartorius, Göttingen, Germany) and analyzed by HPLC 
(LaChromElite, Hitachi, VWR, Darmstadt, Germany) for acetate (Becker et al., 
2009a), sugars, and glycerol (Buschke et al., 2011). Additionally, glucose 
concentration was measured with a biochemical analyzer (YSI 2700 Select, 
Kreienbaum, Langenfeld, Germany). 
 
2.3.9. Quantification of deoxyviolacein 
For extraction of deoxyviolacein from cells, 50 µL broth was thoroughly 
mixed for 2 min with 1.8 mL ethanol and 175 mg glass beads (0.106-0.125 mm 
diameter, Worf Glaskugeln GmbH, Mainz, Germany). Afterwards, cells were 
separated by centrifugation (3 min, 9800×g, 20 °C) and subjected to repeated 
extraction cycles until no more pigment accumulated in the supernatant. All 
ethanol extracts were finally combined and analyzed by HPLC (Rodrigues et al., 
2012). 
 
2.3.10. Purification of deoxyviolacein 
Cells were harvested by centrifugation (30 min, 5346×g, 4 °C). 
Deoxyviolacein was extracted by three cycles of cell homogenization with ethanol 
and extract recovery by centrifugation (30 min, 5346×g, 4 °C). In each cycle, the 
volume of ethanol used corresponded to the initial volume of broth collected. 
Purification of combined extract fractions was done by flash-chromatography using 
silica gel 60 (0.04–0.06 mm diameter, Merck, Darmstadt, Germany) (Rodrigues et 
al., 2012). Ethanol and ethyl acetate were used as mobile phase.   
2.3.11. GC-MS labelling analysis 
Mass isotopomer fractions of proteinogenic amino acids were quantified by 
GC-MS (Wittmann et al., 2004; Wittmann et al., 2007). Biomass samples of 1 mg 
were hydrolyzed for 12 h in 50 μL 6 M HCl and subsequently filtrated (0.22 μm 
Ultrafree MC GV Durapore PVDF, EMD Millipore Corporation, Billerica, MA, USA). 
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Samples were dried at 20 °C under a stream of N2 and then solubilized in 50 μL 
dimethylformamide (0.1% pyridine). For derivatization, 50 μL N-methyl-N-t-
butyldimethyl-silyl-trifluoroacetamide (MBDSTFA; Macherey-Nagel, Düren, 
Germany) was added, following incubation at 80 °C for 30 min. After derivatization, 
samples were centrifuged (1 min, 9800 × g, 20 °C) and the supernatant was 
analyzed by GC-MS (Agilent Technologies, Santa Clara, CA, USA). All 
measurements were first conducted in scan mode to exclude isobaric overlay with 
the analytes of interest. Mass isotopomer distributions were then quantified with 
selective ion monitoring (Wittmann, 2007). 
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3 Results 
3.1. HPLC-based separation and quantification of violacein 
and deoxyviolacein 
3.1.1. Evaluation of photometric measurement of crude 
violacein 
To evaluate the suitability of the widely applied spectrophotometric method 
for the analysis of the pigment content, the extinction coefficient was determined 
for different mixtures of the two compounds. This revealed an almost 50% change 
of the extinction coefficient in mixtures with increasing concentration of violacein 
  
 
Figure 5. Analysis of violacein and deoxyviolacein: Extinction coefficients for mixtures of violacein 
and deoxyviolacein (A), HPLC analysis of violacein (B), deoxyviolacein (C) and a mixture (D) on a 
C18 column with 50% (v v
-1
) ethanol as mobile phase. The samples reflect standard solutions of 
6.0 mg L
-1
 violacein (B), 19.5 mg L
-1
 deoxyviolacein (C) and 1:1 (v v
-1
) mix of both (D). The 
respective UV-Vis spectrum is presented for each peak. For measurement of extinction 
coefficients, the pigments were dissolved in ethanol and analyzed at λ = 575 nm. 
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from 0 to 100% (Figure 5A), which has not been considered so far. Clearly, this 
can result in up to a 50% error in the estimated total pigment amount from 
photometric readouts. Beyond that, the method fails to resolve the two products, 
information that is highly relevant for screening of novel isolates as well as 
optimization of strains and processes. 
3.1.2. Development of an HPLC method for quantification of 
violacein and deoxyviolacein 
As violacein and deoxyviolacein are soluble in ethanol (Mendes et al., 
2001), different concentrations of this alcohol in HPLC-grade water were tested as 
mobile phase in the HPLC analysis. The use of 50% (v v-1) ethanol resulted in 
single peaks for violacein and deoxyviolacein for all concentrations tested, i.e. 
ranging from 5-50 mg L-1 violacein and 0.5-150 mg L-1 deoxyviolacein as given in 
Figure 5B, C and D. By variation of the concentration of ethanol between 50 and 
100 % (v v-1) in the mobile phase, it was possible to influence the retention time for 
both compounds towards an improved separation. The use of 50% (v v-1) ethanol 
as mobile phase allowed optimum separation, as shown in the chromatogram of a 
standard mixture of the pigments (Figure 5D). The values of the concentrations of 
violacein and deoxyviolacein calculated for this mixture were consistent with that 
of the pure standard solutions used to make the mixture (Figure 5B and C), 
demonstrating that the pigments could be totally separated. For both compounds, 
linear calibration curves were obtained. For the UV signal at 580 nm a correlation 
coefficient of 0.99 resulted in each case. The slopes of the calibration curves of 
violacein and deoxyviolacein were 4.57 × 10-6 and 7.06 × 10-6, respectively. 
Methanol, previously described as solvent for analysis of violacein (Jiang et al., 
2010), was also tested, but did not provide defined peaks for the pigments. With 
increasing concentrations of the violacein and deoxyviolacein standards, more 
than two peaks were observed in the chromatogram, which did not yield useful 
calibration curves. A similar effect was described previously (Rettori and Durán, 
1998). Moreover, violacein and deoxyviolacein partly precipitated from solutions in 
methanol, when the temperature of the auto sampler was set below 20 °C, which 
is problematic for the processing of bio-analytical samples. This was not the case 
for solutions in ethanol.   
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3.1.3. Quantification of violacein and deoxyviolacein in 
microbial cultures 
The developed approach was tested for plate grown cultures of E. coli 
harboring two different plasmids as well as the natural producer J. lividum. For all 
microbial strains the two pigments could be precisely quantified, revealing that the 
relative fraction of violacein and deoxyviolacein strongly depend on the genetic 
background of the production strain (Table 6). 
 
Table 6. Production of violacein and deoxyviolacein by different strains cultivated on LB agar for 2 
weeks. 
Strain 
Violacein 
(mg L
-1
) 
Deoxyviolacein 
(mg L
-1
) 
Relative 
fraction of 
violacein 
(%)
b
 
Relative fraction 
of 
deoxyviolacein 
(%) 
Crude violacein 
(mg L
-1
) 
E. coli TOP 10 pJP1000 23.5 ± 0.0 1.1 ± 0.1  96  4 24.6 ± 0.1 
E. coli TOP 10 pPSX-Vio+   6.0 ± 0.0 n.d.
a
        100   0   6.0 ± 0.0 
J. lividum DSM 1522 16.3 ± 0.1 4.2 ± 0.0 79 21 20.5 ± 0.1 
a
 not detectable (the limit of detection was < 0.1 mg L
-1
). 
b
 relative to the sum of violacein and deoxyviolacein concentrations. 
 
During the cultivation of J. lividum DSM 1522 in liquid medium, both pigments 
accumulated in the broth, whereby the ratio between violacein and deoxyviolacein 
remained constant (Figure 6). 
 
 
Figure 6. Violacein and deoxyviolacein production profiles of J. lividum DSM 1522 cultivated in LB 
medium with 1% (w v
-1
) glycerol at 25 °C. 
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3.2. Systems metabolic engineering of Escherichia coli for 
production of violacein and deoxyviolacein 
3.2.1. Construction of a basic strain for deoxyviolacein 
production  
The first step of the present work was the genetic construction of a basic 
recombinant production strain. For this purpose, E. coli K-12 MG1655 was 
transformed with the plasmid pBvioABCE-Km that contained the deoxyviolacein 
pathway genes from C. violaceum ATCC 12472. The obtained mutant, designated 
E. coli dVIO-1 (Table 2) exhibited violet colonies, when grown on agar plates with 
L-arabinose, the inducer of the deoxyviolacein genes (Figure 7). 
 
 
 
 
Figure 7. Control of the deoxyviolacein production in E. coli dVio-1, using the AraC system and L-
arabinose as inducer for vioABCE expression: plate-grown cells on complex LB medium with 
kanamycin (A) and on complex LB medium with kanamycin and L-arabinose (B).  
 
This was a first indication that the pathway was functionally expressed in E. coli. In 
liquid culture with L-arabinose as sole source of carbon (10 g L-1), incubated at 20 
°C, the novel strain was able to produce 176.1 ±5.9 mg L-1 of deoxyviolacein 
(Figure 8A). The desired product was formed from early on, whereby production 
seemed associated to the growth of the cells. During the cultivation, L-arabinose 
was completely consumed. The cells accumulated acetate during the first phase, 
but later re-utilized the by-product together with L-arabinose. Violacein was not 
detected, indicating desired formation of the pure deoxyviolacein (Figure 9B). 
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Figure 8. Growth and production profile of recombinant E. coli dVio-1 (A), dVio-6 (B), and TRP11 
(C) in mineral medium containing 10 g L
-1
 L-arabinose as carbon and energy source. n=3. 
 
During the whole process, the dissolved oxygen level remained above 80% of 
saturation (Figure 8A). This showed that the cells were sufficiently supplied with 
oxygen, which obviously did not limit the production, and could be excluded as 
triggering agent for acetate overflow. This was in line with an unaffected growth 
and production behavior at reduced shaking rates of 100 and 50 rpm (data not 
shown). 
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3.2.2. Evaluation of deoxyviolacein and violacein analytics  
As shown, the recombinant strain accumulated about 180 mg L-1 of 
deoxyviolacein (Figure 8A). In contrast to HPLC based quantification of the 
product, performed here, deoxyviolacein and violacein are typically monitored via 
photometric analysis of extracts that contain the pigment. Depending on the wave-
length applied, different extinction coefficients are reported to estimate the 
concentration. The parallel analysis of deoxyviolacein extracts and solutions with 
the purified compound revealed that photometric measurement strongly over 
estimates the level of deoxyviolacein by up to 320% (Table 7). In the case of 
violacein this amounts up to about 680% (Table 8). Accordingly, all further 
analytics relied on HPLC measurement to ensure accurate data. 
 
 
 
Figure 9. HPLC based analysis of violacein and deoxyviolacein. The chromatograms display a 
purified deoxyviolacein standard (A), an extract from the culture broth of E. coli dVio-1 (B), a 
purified violacein standard (C), and an extract from the culture broth of E. coli Vio-4 (D). The eluting 
compounds represent violacein (1) and deoxyviolacein (2). 
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Table 7. Revision of analytical approaches for the quantification of deoxyviolacein. The evaluation 
investigated pure standard solutions of the analyte with absolute concentrations of 3.7 mg L
-1
 
(standard 1), 7.7 mg L
-1
 (standard 2) and 38.3 mg L
-1
 of deoxyviolacein and one extract from the 
cultivation broth of the recombinant producer E. coli dVio-6, which were analyzed in parallel by 
HPLC (Rodrigues et al., 2012) and photometrical measurement at a wavelength of 560 nm (Jiang 
et al., 2012). The latter recruited the reported extinction coefficient of ε560 = 15.955 L (g cm)
-1 
to 
estimate the deoxyviolacein content. Concentrations given are mean values and deviations from 
three replicates. 
 
Sample 
HPLC  
(mg L
-1
) 
Photometry at 560 
nm 
(mg L
-1
) 
Correlation factor  
Standard 1   3.7 ±0.0      11.8 ±0.0  3.2 
Standard 2   7.7 ±0.1     24.8 ±0.2 3.2 
Standard 3 38.3 ±0.0           122.7 ±0.1   3.2 
Broth extract of dVio-6 21.1 ±0.0     64.6 ±0.0 3.1 
 
 
Table 8. Revision of analytical approaches for the quantification of violacein. The evaluation 
investigated pure standard solutions of the analyte with absolute concentrations of 3.2 mg L
-1
  
(standard 1), 6.4 mg L
-1
 (standard 2) and 12.8 mg L
-1
 of violacein and one extract from the 
cultivation broth of the recombinant producer E. coli Vio-4. These were analyzed in parallel by 
HPLC (Rodrigues et al., 2012) and by photometry at 570 nm with ε570 = 10.955 L (g cm)
-1 
(photometry 1, (Wang et al., 2009)), at 575 nm with ε575 = 56.010 L (g cm)
-
1 (photometry 2, 
(Mendes et al., 2001)), and at 575 nm with ε575 = 29.700 L (g cm)
-1
 (photometry 3, (Durán et al., 
2007)). Concentrations given are mean values and deviations from three replicates. The correlation 
factors (from left to right) relate HPLC to the different photometrical assays. 
 
Sample 
HPLC  
(mg L
-1
) 
Photometry 1
 
(mg L
-1
) 
Photometry 
2  
(mg L
-1
) 
Photometry 
3  
(mg L
-1
) 
Correlation 
factors  
Standard 1   3.2 ±0.0    21.8 ±0.0    4.3 ±0.0     8.1 ±0.0 6.8 / 1.3 / 2.5 
Standard 2   6.4 ±0.0     43.1 ±0.1    8.5 ±0.0   16.0 ±0.0 6.7 / 1.3 / 2.5 
Standard 3 12.8 ±0.1     86.4 ±0.1   17.0 ±0.1   32.1 ±0.1 6.7 / 1.3 / 2.5 
Broth extract of 
Vio-4 
25.6 ±0.0   172.4 ±0.2   34.0 ±0.0   64.2 ±0.0 6.7 / 1.3 / 2.5 
Results 
 
 57 
3.2.3. Impact of temperature and chaperone co-expression on 
deoxyviolacein production by recombinant E. coli  
It was interesting to note that the temperature had a pronounced effect on 
deoxyviolacein production. At 20 °C, the production was highest. Elevated 
temperatures improved the overall growth of the recombinant strain, but 
significantly reduced the product level to 14.5% at 30 °C and even 0.2% at 37 °C. 
This behavior, at least potentially, indicated stability or folding problems of the 
heterologous proteins introduced into the host. Different chaperones were 
therefore co-expressed in the producing strain. However, none of the candidates 
tested, i.e. DnaK, DnaJ, GrpE, GroES, GroEL, and Tig, improved the 
deoxyviolacein titer beyond the optimum at 20 °C. At 30 °C, the chaperones 
showed a positive effect, which pointed towards folding problems of the 
heterologous enzymes at higher temperature (Figure 10). However, the maximum 
product level corresponded to only 43% of the highest value observed at 20 °C. 
 
 
 
Figure 10. Effect of chaperone co-expression on deoxyviolacein production by recombinant E. coli 
dVio-1 at 30 °C. The expressed chaperones correspond to the different plasmids (Table 2) used, 
i.e. pGro7 (groES groEL). Their expression was induced by addition of tetracycline (tet) and/or L-
arabinose (ara). The dashed line marks the level of the basic producer at 20 °C. n=3. 
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3.2.4. Quantification of intracellular precursor availability by 
targeted metabolite analysis  
L-Tryptophan, the building block for deoxyviolacein, typically occurs in low 
amounts inside E. coli. It thus appeared relevant in a next step, to investigate the 
impact of its demand for deoxyviolacein production on the intracellular availability. 
For this purpose, the free intracellular pool of L-tryptophan was compared between 
the strain dVio-1 and the control strain (NC) that harbored the empty plasmid 
(Table 2). The analysis involved sampling by fast filtration and subsequent 
extraction in boiling water, a technique that has been previously validated for 
intracellular amino acid analysis in E. coli (Bolten et al., 2007). Whereas the 
control strain did not accumulate any pigment, the producer accumulated almost 
180 mg deoxyviolacein L-1 (Figure 11A). It turned out, that the level of intracellular 
tryptophan was decreased by 63% as response to deoxyviolacein production 
(Figure 11B). Obviously, L-tryptophan could not be efficiently replenished to 
account for the withdrawal into the implemented pathway. Due to the fact, that the 
enzyme VioA exhibit a rather low (KM of 31 ±11 μM) affinity for L-tryptophan 
(Balibar and Walsh, 2006), this likely limited the performance of the producer and 
displayed a promising target for the improvement of deoxyviolacein production in 
E. coli. L-Serine, as up-stream intermediate, is also involved in the supply of L-
tryptophan. The L-serine level also decreased in response to deoxyviolacein 
production (Figure 11C). Due to this, next rounds of strain engineering focused on 
increasing the intracellular availability of L-tryptophan and L-serine in supporting 
pathways of the carbon core metabolism of E. coli, upstream of the novel 
heterologous pathway. 
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Figure 11. Deoxyviolacein titer (A) and intracellular levels of tryptophan (B) and serine (C) in the 
parent strain E. coli NC (control), the recombinant producers dVio-1 through dVio-6, and the 
tryptophan producer TRP11 (Table 2) in L-arabinose mineral medium. n=3. 
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3.2.1. Design of feedback-resistant enzymes in supporting 
pathways 
Tryptophan synthesis in E. coli is controlled by several layers of regulation, 
i.e. by repression (trpR), attenuation (trpL), and feedback-inhibition of enzymes 
(Sprenger, 2007). Elimination of the corresponding genomic elements appeared 
straightforward to remove the undesired transcriptional control mechanisms, as 
shown below. However, full pathway de-regulation of pathway flux required the 
release from feed-back control. Anthranilate synthase, encoded by the trpE gene, 
is regulated via feedback-inhibition by L-tryptophan. Therefore, a feedback-
resistant form was designed and constructed by site-directed mutagenesis (see 
Appendix) to yield a trpEfr allele. The obtained feedback resistant enzyme variant 
comprised four amino acid exchanges, i.e. Asn168Asp, Cys237Arg, Met293Thr 
and Ala478Thr, respectively. As production of L-serine, which contributes to 
tryptophan synthesis, is also regulated by feedback inhibition exerted upon 3-
phosphoglycerate dehydrogenase by L-serine, a feedback-resistant form (serAfr) 
was also constructed by site-directed mutagenesis, based on experimental 
evidence (Maier and Flinspach). The superior variant exhibited the amino acid 
exchange Thr372Asp.  
3.2.2. Metabolic engineering of tryptophan supply  
The complex network of tryptophan biosynthesis and degradation pathways 
in E. coli suggested a multi-target approach to increase pathway flux. In order to 
improve the intracellular availability of tryptophan, a set of three genetic 
modifications was therefore implemented into the basic producer E. coli dVio-1 
(Table 2, Figure 12). First, the gene for the repressor of the tryptophan operon 
(trpR) was deleted. Moreover, pathways involved in degradation of tryptophan and 
serine were eliminated to enable increased pool sizes. For this purpose, the gene 
tnaA that encodes tryptophanase, responsible for L-tryptophan degradation, and 
the sdaA gene, involved in serine degradation, were deleted. The novel strain E. 
coli dVio-2, comprising (i) the heterologous plasmid, (ii) the de-repressed 
tryptophan pathway and (iii) eliminated degradation routes for the precursors, 
tryptophan and L-serine, respectively, was tested for production (Figure 11A). Most 
strikingly, it exhibited an elevated product titer of 202.8 ±1.2 mg L-1. The success 
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of the chosen strategy was further confirmed by the intracellular levels of 
tryptophan and serine, which were increased by 69.6% and 21.0%, respectively, 
upon the genetic modification (Figure 11B and C).  
 
 
Figure 12. Systems metabolic engineering of violacein and deoxyviolacein production in 
Escherichia coli. Bold, green arrows mark reactions that were amplified by overexpression of the 
encoding genes and de-regulation of feedback controlled reaction steps. Eliminated reactions or 
control mechanisms, obtained by gene deletion are marked in red color. Compound names: G6P 
(glucose 6-phosphate), F6P (fructose 6-phosphate), GAP (glyceraldehyde 3-phosphate), 3PG (3-
phosphoglycerate), PEP (phosphoenolpyruvate), PYR (pyruvate), ACCOA (acetyl-CoA), OAA 
(oxaloacetate), IND (indole) Rul5P (ribulose 5-phosphate), Xyl5P (xylulose 5-phosphate), Rib5P 
(ribose 5-phosphate), Sed7P (sedoheptulose 7-phosphate), E4P (erythrose 4-phosphate), Ser 
(Serine), DAHP (3-deoxy-d-arabino-heptulosonate-7-phosphate), CHO (chorismate), ANTH 
(anthranilate), Trp (tryptophan), IPA (indole-3-pyruvic acid imine), PDVA (protodeoxyviolaceinic 
acid), and AC (acetate). 
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In order to exploit this effect, additional modifications were implemented into the 
tryptophan pathway. As first target, trpL, involved in the attenuation of the trp 
operon (Gu et al., 2012; Henkin and Yanofsky, 2002), was deleted. Subsequently, 
the L-tryptophan pathway was decoupled from feedback control via replacement of 
the native trpE gene by the variant trpEfr ((Caligiuri and Bauerle, 1991), see 
Appendix for details). TrpE catalyzes the first step of the L- tryptophan pathway 
and forms anthranilate from chorismate. Interestingly, these additional 
modifications did not have any further impact on the deoxyviolacein titer and on 
the intracellular tryptophan pool (Figure 11A and B), both of which remained 
almost unchanged in the dVio-3 (209.5 ±17.3 mg L-1 deoxyviolacein, 1.6 ±0.7 µmol 
gCDW-1 L-tryptophan) as compared to the parent strain (202.8 ±1.2 mg L-1 
deoxyviolacein, 1.5 ±0.4 µmol gCDW-1 L-tryptophan). These results suggested the 
preceding chorismate pathway as relevant next target.  
3.2.3. Metabolic engineering of the chorismate supply 
To improve chorismate biosynthesis, the corresponding pathway was 
substantially engineered (Figure 11). First, an extra copy of the aroFBL genes 
(Rüffer et al., 2004) was integrated as an artificial operon into the chromosome of 
E. coli replacing the resident lacIZYA genes to generate strain TRP4 (Table 2). 
The three genes are placed under control of the PTAC promoter (see Suppl. Figure 
3 and Appendix). The construct ∆lac::PTACaroFBL-FRT-Km-FRT was transferred 
into strain E. coli dVio-3 (Table 2). The created strain, designated E. coli dVio-4, 
exhibited a 19.5% increased deoxyviolacein titer of 250.3 ±5.7 mg L-1 (Figure 
11A). It was interesting to note that the tryptophan level of this strain remained at a 
similar level, as compared to the parental producer (Figure 11B), whereby no 
tryptophan accumulated in the broth during the cultivation. Obviously, the extra 
tryptophan produced was fully directed to deoxyviolacein production, suggesting 
an extra capacity of the terminal pathway to receive a further enhanced carbon 
flux. As the modification of the chorismate pathway successfully increased the 
product level, the next genetic modification aimed at improving the availability of 
the chorismate precursor, erythrose 4-phosphate. 
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3.2.4. Metabolic engineering of erythrose 4-phosphate supply  
In arabinose-grown E. coli, erythrose-4-phosphate is provided by the 
enzyme transketolase in the non-oxidative part of the pentose phosphate pathway 
(Sprenger, 1995). It therefore appeared straightforward to amplify the gene for the 
major transketolase, tktA (Sprenger et al., 1995), in order to increase the flux. This 
was realized by inserting the tktA gene, controlled by the PTAC promoter, into the 
genome of E. coli, i.e. the gal locus of strain dVio-4 (Table 2). The resulting over-
producer E. coli dVio-5 (Table 2) achieved an increased deoxyviolacein titer of 
277.0 ±3.5 mg L-1. The tryptophan level inside the cell did not change as 
compared to dVio-4.  
3.2.5. Metabolic engineering of serine supply  
Along the strain genealogy, the intracellular L-serine pool responded in 
rather complex manner to the genetic changes. The overall level in the non-
producing wild type and the best producer E. coli dVio-6 was always the same at 
about 2 µmol (g CDW)-1 (Figure 11C). However, a closer inspection showed that 
the L-serine pool always decreased, when the corresponding genetic modification 
resulted in a strong production increase, i.e. from the control strain to dVio-1, and 
from dVio-3 to dVio-4. This suggested a benefit, if the availability of L-serine could 
be further enhanced. Due to this, the feedback-resistant variant serAfr of the serA 
gene was additionally inserted into the xyl locus (Table 2 and Appendix). The gene 
encodes 3-phosphoglycerate dehydrogenase, responsible for the first step in the 
serine pathway that converts 3-phosphoglycerate into 3-phosphohydroxypyruvate. 
The created mutant E. coli dVio-6 accumulated 324.1 ±2.4 mg L-1 of 
deoxyviolacein (Figure 11A). Upon the increased serine supply, the intracellular 
tryptophan pool raised about fivefold (Figure 11B). No accumulation of L-
tryptophan in the supernatant was observed, as long as L-arabinose was available 
to induce gene expression (Figure 8B). Towards the very end of the process, 
when arabinose had been depleted and the cells switched to re-use acetate, 
tryptophan (55 mg L-1) accumulated in the broth (Figure 8B). In addition, minor 
amounts of L-serine (6 mg L-1) were secreted, together with about 3 mg L-1 of 
glycine.  
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3.2.6. Evaluation of the capacity of carbon core metabolism and 
the heterologous deoxyviolacein pathway  
The appropriate balancing of pathway modules along a biosynthetic chain is 
one of the crucial tasks of successful strain engineering. To investigate the 
underlying characteristics in the designed over-producer, a specific reporter strain 
was generated. This strain, designated E. coli TRP11, corresponded to the 
genotype of the best deoxyviolacein producer, dVio-6, except for the presence of 
the heterologous plasmid pBvioABCE-Km. This strain grew much faster than the 
corresponding producer dVio-6 (Figure 8C). It consumed arabinose within only 
about 75 h, as indicated by the rise in the dissolved oxygen level, and the strain 
secreted about 800 mg L-1 tryptophan. Tryptophan could not be re-utilized due to 
the introduced block of the catabolic pathway. The intracellular levels of tryptophan 
and serine increased twentyfold and twofold, respectively (Figure 11B and C) 
indicating the effectiveness of the strategy employed to improve the intracellular 
levels of these deoxyviolacein and violacein precursors.  
 
3.2.7. Fed-batch production of deoxyviolacein in E. coli dVio-6 
from L-arabinose as carbon source 
In a first experiment, the previously derived strain E. coli dVio-6 (Table 4) 
was evaluated for deoxyviolacein production. L-Arabinose simultaneously served 
as carbon source for growth and as inducer for expression of the plasmid encoded 
deoxyviolacein pathway, whereby the entire process was operated at 20 °C. 
During the initial batch phase, E. coli dVio-6 produced 100 mg L-1 deoxyviolacein 
(Figure 13). When L-arabinose was completely consumed, the feed was started 
and the process was continued. However, the concentration of deoxyviolacein 
increased only slightly further. After about 125 h, L-arabinose began to accumulate 
in the medium, followed by accumulation of acetate. At this time, cell concentration 
decreased. At 210 h of cultivation, the deoxyviolacein titer reached a maximum 
value of 250 mg L-1 (Figure 13). At this point, L-arabinose and acetate had strongly 
accumulated, indicating inhibiting cultivation conditions. E. coli dVio-6 successfully 
produced deoxyviolacein. However, the obtained titer was low. It was even lower 
than that previously obtained in shake-flaks cultivations (Rodrigues et al., 2013). 
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Figure 13. Fed-batch production of deoxyviolacein in E. coli dVio-6. The dashed line marks the 
beginning of the feed phase. The feed rate was adjusted to a constant growth rate of 0.011 h
-1
, 
based on growth parameters (μmax = 0.018 h
-1
, Yx/s = 0.235 g g
-1
) previously obtained (Rodrigues 
et al., 2013). 
 
Moreover, growth of E. coli on L-arabinose was slow, so that the total process took 
more than one week. Taken together, production of deoxyviolacein from L-
arabinose was suboptimal, leaving space and need for improvement. 
 
3.2.8. Elimination of L-arabinose metabolism in producing E. 
coli 
It appeared important to eliminate the breakdown of L-arabinose in 
producing E. coli to allow its exclusive use as inducer for gene expression of the 
heterologous pathway and to hopefully reduce the need for this expensive sugar to 
lower amounts. For this purpose, the following strategy was chosen. First, the 
araBAD genes of E. coli K-12 MG1655 were inactivated by replacement of the 
genomic sequence of araBAD with the chloramphenicol marker. In this procedure, 
the target DNA region between the homology extensions, present in the primers, 
was totally removed. Chloramphenicol resistant clones, obtained from E. coli K-12 
MG1655 after deletion, were analyzed by fragment size PCR. On basis of the 
used primer pairs, the expected fragment size of the PCR product was 1875 bp for 
the deletion strain, and 4986 bp for wild type, respectively. Electrophoretic analysis 
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of the PCR products of wild-type and one of the chloramphenicol resistant clones 
indeed revealed the expected sizes (Figure 14).  
 
 
 
Figure 14. Validation of genetic modifications in deoxyviolacein producing E. coli dVio-8: deletion 
of araBAD (A) and of trpR (B). Lanes 1-3 show PCR products for validation of araBAD deletion in 
strains MG1655 (1), ∆araBAD (2), and dVio-8 (3). Lanes 4-6 show PCR products for validation of 
trpR deletion in strains MG1655 (4), ∆araBAD (5), and dVio-8 (6). 
 
The clone, in which araBAD was removed was then used to obtain a P1vir lysate. 
The latter was applied to integrate the construct ∆araBAD::FRT-Cm-FRT into E. 
coli TRP11. The created strain was designated E. coli dVio-7 (Table 4). E. coli 
dVio-7 was transformed with the biosynthetic deoxyviolacein pathway plasmid 
(pBvioABCE-Km). This yielded the desired producer E. coli dVio-8. E. coli dVio-8 
showed the shortened PCR product that corresponded to successful deletion of 
araBAD (Figure 14). Additionally, the mutant was no more able to grow in mineral 
medium with L-arabinose as sole carbon and energy source (Figure 15B), as 
opposed to its parent E. coli dVio-6 (Figure 15A). Cultivation in complex medium 
with L-arabinose as inducer served to evaluate the metabolic engineering strategy 
with regard to production of the antitumor drug. 
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Figure 15. Growth of E. coli strains dVio-6 (A) and dVio-8 (B) in mineral medium with L-arabinose 
as single carbon source. Cultivations were performed in shaken flasks (n=3).   
 
E. coli dVio-8, grown on LB plates containing L-arabinose, formed violet pigmented 
colonies (Figure 16). This proved that L-arabinose was obviously taken up by the 
cells and induced gene expression for deoxyviolacein production. 
 
 
 
Figure 16. E. coli dVio-8 is grown on LB agar plates with L-arabinose as inducer of gene 
expression of the biosynthetic deoxyviolacein pathway. Pigmentation of the colonies verifies 
successful induction of the heterologous operon.  
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3.2.9. Verification of deletion of the gene of the tryptophan 
repressor, TrpR 
Transduction with the phage P1vir system can potentially transfer up to 100 
kbp (Thomason et al., 2007). As the distance between the deleted araBAD locus 
and the ∆trpR mutation, implemented in E. coli dVio-8 to de-bottleneck the 
tryptophan pathway, was only about 80 kbp, it could not be excluded that the wild-
type trpR from the donating strain E. coli ∆araBAD (Table 4) was co-transduced 
undesirably, thereby reducing the ability to produce the deoxyviolacein precursor 
L-tryptophan. Therefore, deletion of trpR in E. coli dVio-8 was additionally checked 
by PCR. In this case, an amplicon with either 638 bp or 897 bp should be 
observed for deletion of trpR or wild-type, respectively. The PCR results 
demonstrate that E. coli dVio-8 still carried the ∆trpR modification, as compared to 
the negative control E. coli MG1655 (Figure 14).  
 
3.2.10. Evaluation of deoxyviolacein production on different 
carbon sources 
In order to evaluate production of deoxyviolacein in E. coli dVio-8, 
microplate cultivations were performed. Either 10 g L-1 fructose or glycerol 
replaced L-arabinose as carbon source. Hereby, different concentrations of L-
arabinose were tested for induction of gene expression. Glucose was not 
considered, because it inhibits expression of the araBAD promoter by catabolite 
repression (Desai and Rao, 2010). Both, fructose and glycerol enabled efficient 
growth of the recombinant E. coli strain. Using fructose as carbon source, 
maximum cell concentration was reached after 23-30 h of cultivation time, 
depending on the L-arabinose level (Figure 17A). It was interesting to note that 
higher levels of L-arabinose seemed to suppress growth. A similar trend was also 
observed for glycerol. The time required to reach maximal cell concentration on 
glycerol correlated with L-arabinose concentration (Figure 17B). Samples for 
determination of deoxyviolacein were collected, when cultures had reached 
stationary phase. On fructose, the deoxyviolacein titer increased up to 250 mg L-1 
with increasing initial L-arabinose level (Figure 17C). In case of glycerol, a  
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Figure 17. Impact of fructose (A) and glycerol (B) as carbon source on growth and deoxyviolacein 
production in E. coli dVio-8. Different levels of L-arabinose (10-500 mg L
-1
) were tested to identify 
optimum inducing conditions for deoxyviolacein production (C). Cultivations were performed in 
microplates (n=3).   
 
maximum deoxyviolacein concentration of even 370 mg L-1 was reached. Here, 
already 100 mg L-1 L-arabinose were found sufficient for induction. As use of 
glycerol clearly permitted a higher titer, this compound was selected as preferred 
carbon source for further production. 
 
3.2.11. Investigation of remaining L-arabinose turnover in E. 
coli ∆araBAD using 13C labeling experiments 
As sole source of carbon, L-arabinose did not support growth of the 
producer E. coli dVio-8, which lacked the araBAD operon. However, it appeared 
possible that L-arabinose was still co-metabolized by the recombinant cells in 
presence of a second fully functional carbon source, such as glycerol. In such a 
case, one would expect L-arabinose carbon in other metabolic intermediates and, 
consequently, in amino acids derived therefrom. Based on this hypothesis, the 
following isotope experiment was done to clarify the metabolic fate of L-arabinose 
in E. coli lacking araBAD. E. coli dVio-6 and dVio-8 were independently cultivated 
with glycerol as primary carbon source, together with either L-[1-13C] arabinose or 
naturally labeled L-arabinose. The labeling pattern of proteinogenic amino acids of 
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E. coli dVio-6, which carried a functional araBAD pathway, was significantly 
enriched in 13C, when L-[1-13C] arabinose was used, as compared to the non-
labeled control (Figure 18A).  
 
 
Figure 18. Elucidation of L-arabinose catabolism in E. coli dVio-6 (A) and dVio-8 (B). Strains were 
cultured in media containing non-labeled or 99% L-[1-
13
C] arabinose, respectively. Metabolization 
of L-arabinose was assessed by 
13
C labeling analysis of amino acids from the cell protein.  
 
Obviously, the strain catabolized L-arabinose in presence of other medium 
ingredients so that its carbon skeleton entered central metabolism and 
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biosynthetic pathways of amino acids. In contrast, E. coli dVio-8, which lacked the 
araBAD metabolic route, did not show any 13C enrichment, when cultivated on 13C-
labelled L-arabinose (Figure 18B). For all amino acids analyzed, the labeling 
pattern was identical to that of the non-labeled control. This demonstrated the 
inability of strain E. coli dVio-8 to convert L-arabinose, even in presence of other 
nutrients.  
 
3.2.12. Glycerol-based fed-batch production of deoxyviolacein 
by E. coli dVio-8 
For production of deoxyviolacein, E. coli dVio-8 was transferred into a fed-
batch set-up. The process design comprised two phases: an initial growth phase 
at 37 °C and a second production phase at 20 °C (Figure 19).  
 
 
Figure 19. Fed-batch production of deoxyviolacein in E. coli dVio-8. The arrow indicates the time 
point of glucose depletion, at which the reactor was cooled from 37°C to 20°C and the carbon 
source was switched to glycerol. The dashed line marks the beginning of the feed phase. 
 
During the initial phase at 37 °C, production of deoxyviolacein was completely shut 
off, because glucose was used as carbon source (Desai and Rao, 2010). After 10 
h, glucose was completely consumed. Temperature was then shifted to 20 °C 
(Rodrigues et al., 2013). When the reactor had reached 20 °C, glycerol-based 
medium was added and cells switched to use this as carbon source and started to 
produce deoxyviolacein. Upon depletion of the batched glycerol, pulse-wise 
feeding of glycerol started. After about 200 h, a deoxyviolacein titer of 1.6 g L-1 
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was reached; alongside with a maximal cell concentration of 17.7 (g dry biomass) 
L-1. L-Arabinose was available throughout the whole process. At the end of 
cultivation, 150 mg L-1 L-arabinose was still left, as determined by HPLC. The 
acetate level remained below 1 g L-1 during the process and no accumulation of 
glycerol was observed. When the filling volume approached the maximal working 
volume, the process was stopped. Subsequently, deoxyviolacein was extracted 
from the recovered cells, concentrated and purified. HPLC analysis demonstrated 
highly pure deoxyviolacein (> 99.5%, Figure 20). Overall, the yield of 
deoxyviolacein on glycerol was 20 mg g-1 and the productivity was 8 mg L-1 h-1. 
 
 
Figure 20. Validation of purity of deoxyviolacein after extraction from culture broth and purification 
by flash chromatography. The signals of the sample reflect the dead volume of the column (1) and 
the target compound deoxyviolacein (2). The peak areas reveal a purity of > 99.5%. Analysis was 
conducted with HPLC and detection with a diode array detector. 
 
3.2.13. Extension of the product spectrum to violacein  
In order to engineer a strain of E. coli for production of violacein, the 
biosynthetic cluster was completed by the vioD gene using the following strategy. 
The vioD gene of J. lividum was cloned under control of the PTAC promoter and 
inserted into the fuc locus of E. coli BW25113. The strain obtained (strain Vio-1, 
Table 2) was used to integrate the construct ∆fuc::PTACvioD-FRT-Km-FRT into the 
genome of the strain TRP11, which already encoded all beneficial modifications of 
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the supporting pathways. Subsequently, the resistance marker Km was removed 
and the full violacein pathway was restored by transformation with the plasmid 
pBvioABCE-Km (Table 2). The resulting mutant E. coli Vio-4 was evaluated for 
violacein production. HPLC analysis of the extracted culture broth, harvested at 
the end of the process, revealed that the product spectrum was successfully 
switched. Violacein was the only compound, whereas deoxyviolacein was 
completely eliminated (Figure 9D).  
 
3.2.14. Production performance of the designed violacein 
mutant in a fed-batch process  
The potential of the novel mutant was next evaluated under industrial 
production conditions. In order to reach higher cell concentration, a fed-batch 
process was designed. The production medium was enriched with yeast extract 
and tryptone to avoid eventual nutrient limitations during the process and further 
support growth. During the initial batch phase, E. coli Vio-4 completely consumed 
arabinose and produced 70 mg L-1 violacein (Figure 21). With the depletion of the 
carbon source after 48 h, the feed-phase was initiated. Based on the growth 
performance from preceding shake flask cultivations, the exponential feed was 
adjusted such that the cells grew at a constant specific growth rate of 0.011 h-1. 
 
 
 
Figure 21. Fed-batch production of violacein by recombinant E. coli Vio-4. The values, given for 
feed-batch phase are normalized by the initial medium volume to account for dilution of the 
medium. 
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Within 200 h, the cells reached an optical density of almost 70. Violacein 
reached a final level of 710 mg L-1 (Figure 21). During the later process stages, 
acetate accumulated in the medium, which probably inhibited further growth and 
pigment production. Due to the reduced performance at this time point, the 
externally added L-arabinose was no longer fully utilized, but also increased in the 
broth, which leaves space for future improvement. Violacein was the exclusive 
heterologous product, as verified by HPLC analysis (data not shown). The cells 
were harvested from the bioreactor, followed by extraction into ethanol, drying, 
and crystallization of the product in a mixture of acetone and water. The product 
exhibited a purity of 99.8 %, as evaluated by HPLC analysis (Figure 22). No traces 
of deoxyviolacein were detected.   
 
 
 
Figure 22. Purification of violacein: crystallized violacein (A) and chromatogram of the violacein 
crystals, solubilized in ethanol (B).  
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4 Discussion 
4.1.1. HPLC method for quantification of violacein and 
deoxyviolacein  
A method that enables the quantification of the exact content of violacein 
and deoxyviolacein in ethanol extracts of culture samples was developed. This is 
an important contribution to future screening of novel isolates, the evaluation of the 
effects of medium modification, or studies on metabolic engineering or process 
engineering regarding the production of these relevant pigments. It appears likely, 
that also other pathway intermediates, not considered so far, might be detected by 
the developed method, further extending its application range. 
 
4.1.2. The synthetic E. coli based producers enable efficient 
and safe production of violacein and deoxyviolacein  
Systems-wide metabolic pathway engineering enabled pure and efficient 
production of violacein and deoxyviolacein in tailor-made recombinant E. coli 
strains. Both pigments receive high interest due to their biological action against 
pathogenic bacteria, viruses and various tumor cells, so that the present work is a 
milestone towards their tailor-made synthesis. However, natural microbial 
producers of the pigments exhibit low productivity (Yang et al., 2011), 
spontaneous formation of non-producing variants (Jiang et al., 2010) and have 
been shown to cause human infections with high mortality (Patjanasoontorn et al., 
1992; Ti et al., 1993). Safety, well-known genetics, high transformation efficiency, 
cultivation simplicity, rapidity and inexpensiveness contribute to the preferred 
selection of E. coli as recombinant host for therapeutics (Ajikumar et al., 2010; 
Saïda et al., 2006). More than 20 years ago, the pioneering expression of the 
violacein pathway opened the door to obtain violacein and deoxyviolacein in this 
widely accepted host (Pemberton et al., 1991).  
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4.1.3. Systems metabolic engineering of supporting pathways 
drives secondary metabolite production  
The design of the novel strains, described here, involved global optimization 
of supporting biochemical reactions from pentose phosphate pathway, serine, 
chorismate and tryptophan biosynthesis (Figure 12). This almost doubled the 
production as compared to the basic producer. In this line, the designed strains 
display a next level of producers beyond recent attempts that exclusively 
expressed the heterologous pathway (August et al., 2000). Such strains showed 
rather weak performance, which underlines the importance to apply systems 
metabolic engineering for production of high-value pharmaceuticals in recombinant 
hosts (Korneli et al., 2013). Towards further optimization of the developed strains, 
increased expression of the serine pathway enhanced the intracellular tryptophan 
level and the product titer. This points at the genes sdaB and tdcG, responsible for 
serine catabolism in E. coli as promising targets (Li et al., 2012). The inactivation 
of these genes, together with deletion of sdaA, previously increased the serine 
concentration from 0.03 to 0.13 mmol gCDW-1 in E. coli (Li et al., 2012). Recent 
examples have impressively demonstrated the power of systems metabolic 
engineering for microbial overproduction of primary metabolites (Olano et al., 
2008; Park et al., 2007; Sawada et al., 2010; Tyo et al., 2010). As shown, this 
strategy is also valuable for secondary metabolites. Clearly, the synthesis of such 
heterologous compounds is driven by up-stream metabolic engineering of 
supporting pathways that supply building blocks, energy and cofactors. 
 
4.1.4. The arabinose-inducible system mediates stable 
expression of the heterologous pathway  
A bio-based process typically comprises several stages of seed cultivation 
prior to the production itself. Previously, recombinant E. coli strains suffered from 
instable production characteristics, when the cells went through sequential 
cultivations with actively expressed vio genes (August et al., 2000). In the present 
work, this was overcome by an inducible expression control, so that the cells 
maintained high productivity throughout the entire production process. Many 
available inducible expression systems use lac-derived promoters from E. coli that 
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exhibit relatively low level of inducible expression and leaky basal expression 
(Zhang et al., 2012). In light of the previous findings, this would have been 
undesired for production of violacein and deoxyviolacein, so that the particularly 
chosen strategy aimed at a tight control of heterologous expression, using the 
araBAD promoter in combination with arabinose as inducer. The araC protein is an 
efficient repressor in the absence of arabinose, but acts to induce gene 
expression, when the sugar is present (Lee et al., 1987). This allowed silencing 
the cluster during all pre-cultivation stages and activating its expression on 
demand. The beneficial performance of the arabinose-inducible expression system 
has recently also been described for other microorganisms (Zhang et al., 2012) 
suggesting a broader use in the future. The removal of the arabinose degradation 
pathway in E. coli seems promising for further engineering, as it would allow using 
only small amounts of this sugar as inducer in combination with cheaper carbon 
sources, as well as faster growth. In addition, alternative inducible promoters could 
be of interest to suppress basal expression at high induction efficiency (Saïda et 
al., 2006).  
4.1.5. The comparative evaluation of deoxyviolacein and 
violacein production should consider the analytical method 
used  
The method of choice for determination of deoxyviolacein and violacein 
concentrations is photometrical analysis of broth extracts with organic solvents 
(Rodrigues et al., 2012). Although such approaches allow fast and simple 
measurement, one should notice that they can result in over estimation of product 
titers. The comparison with HPLC-based analysis of the separated products, used 
here, revealed that optical protocols cause threefold overestimation for 
deoxyviolacein (Table 7). Violacein titers were up to sevenfold higher, when 
assessed by photometric measurement (Table 8). This provides guidelines for the 
evaluation and comparison of violacein and deoxyviolacein producers and 
processes. Obviously, accurate quantification requires separation of the analyte of 
interest from the broth, as realized during HPLC analysis, to eliminate matrix 
effects. In this regard, the obtained correlation factors between the different 
analytical protocols might be used to correct for overestimation from photometric 
assays. 
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4.1.6. Production of deoxyviolacein using glycerol as carbon 
source 
Here, we describe a novel strain of E. coli that produces 1.6 g L-1 from 
glycerol as carbon source in a fed-batch process. The titer is five-fold higher than 
achievements until now (Rodrigues et al., 2013) and the successful surpassing of 
the gram scale displays an important benchmark for heterologous production of 
high-value drugs in E. coli. Most relevant, the novel process opens the door to 
provide deoxyviolacein with high purity and quantity for biological tests, as well as 
for subsequent chemical modification towards novel biological functions. Such 
advanced tests require supply in gram scale (Koehn and Carter, 2005). The use of 
E. coli is particularly attractive, because it is safe for production of pharmaceutical 
compounds intended for human treatment (Ferrer-Miralles et al., 2009). 
A central achievement of our study is decoupling of production from L-
arabinose as carbon source. The elimination of arabinose catabolism disrupts L-
arabinose and carbon core metabolism of E. coli. In the novel strain, the expensive 
pentose is fully available for induction of heterologous gene expression so that its 
supply can be strongly reduced (Figure 23). The optimized metabolism enables 
the use of other carbon sources. We demonstrate that glycerol is an excellent 
carbon source to drive deoxyviolacein production in E. coli. From an economic 
perspective, glycerol is a highly promising raw material (Yang et al., 2012). It is 
widely available as a side product from biodiesel industry, due to growing demand 
for renewable transportation fuels. The low price for glycerol has recently opened 
a range of applications, including bio-based production of bulk chemicals such as 
lactic acid (Mazumdar et al., 2013) and succinic acid (Blankschien et al., 2010) or 
aromatic compounds (Martínez-Gómez et al., 2012), such as L-phenylalanine 
(Weiner et al., 2014). Thus, production of deoxyviolacein from glycerol is 
promising, particularly, regarding larger scales. From a metabolic viewpoint, 
glycerol is channeled into central metabolism at the level of dihydroxyacetone 
phosphate (Figure 23). With only one biochemical reaction (triosephosphate 
isomerase), this intermediate is converted into glyceraldehyde 3-phosphate, the 
starting precursor of deoxyviolacein. The tight connection of substrate influx and 
product formation might explain the excellent performance of glycerol-grown E. 
coli for deoxyviolacein synthesis (Figure 17, Figure 19). Obviously, the 
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overexpressed transketolase directly acts at the crossroad of substrate entry and 
production biosynthesis, so that carbon is pushed towards the desired product. 
The entire flux, channeled into the tryptophan pathway is utilized for 
deoxyviolacein production, as no tryptophan accumulated as side product 
(Rodrigues et al., 2013). This reveals high capacity of the engineered production 
route and underlines the synthetic power of the genomic traits, implemented in E. 
coli dVio-8 (Figure 23).  
 
Figure 23. Systems metabolic engineering strategy for deoxyviolacein production in E. coli dVio-8, 
using glycerol as carbon source and L-arabinose as inducer. Compound names: G6P (glucose 6-
phosphate), F6P (fructose 6-phosphate), GAP (glyceraldehyde 3-phosphate), 3PG (3-
phosphoglycerate), PEP (phosphoenolpyruvate), PYR (pyruvate), ACCOA (acetyl-CoA), OAA 
(oxaloacetate), IND (indole), Rul5P (ribulose 5-phosphate), Xyl5P (xylulose 5-phosphate), Rib5P 
(ribose 5-phosphate), Sed7P (sedoheptulose 7-phosphate), E4P (erythrose 4-phosphate), Ser (L-
serine), DAHP (3-deoxy-D-arabino-heptulosonate-7-phosphate), CHO (chorismate), ANTH 
(anthranilate), Trp (L-tryptophan), IPA (indole-3-pyruvic acid imine), PDVA (protodeoxyviolaceinic 
acid), and AC (acetate). 
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Studies that focus on overproduction of tryptophan (Shen et al., 2012) and related 
metabolites (Balderas-Hernández et al., 2009; Patnaik and Liao, 1994; Patnaik et 
al., 1995) in E. coli provide valuable information that can guide further metabolic 
engineering. As example, production of tryptophan by E. coli in a fed-batch 
process was increased to 40 g L-1 after overexpressing genes, encoding for 
transketolase (tktA) and phosphoenolpyruvate synthase (ppsA) (Shen et al., 
2012). Joint overexpression of ppsA, aroG and tktA was also beneficial for 
generation of 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP), a common 
precursor of aromatic amino acids in E. coli (Patnaik et al., 1995). E. coli dVio-8 
has two of the three genes overexpressed: tktA and aroF, catalyzing the same 
biochemical reaction as aroG. In this line, ppsA appears as promising target for 
further improvement of deoxyviolacein production in E. coli dVio-8.  
The proven use of different raw materials for efficient production of violacein 
(Rodrigues et al., 2013) and deoxyviolacein (this work) points at high flexibility and 
capacity of E. coli metabolism. The engineered core machinery of E. coli dVio-8 
allows to direct different substrates of interest towards the desired products. In this 
line, the created metabolic chassis is not restricted to production of violacein 
(Rodrigues et al., 2013) and deoxyviolacein (this work), but at the same time, 
enables access also to other L-tryptophan derived drugs with benefits already 
implemented, including rebeccamycin and staurosporine, both important antitumor 
molecules (Howard-Jones and Walsh, 2006). Such a versatility of producing 
strains is highly desirable as it provides a higher degree of freedom for process 
changes and speeds up development by taking full advantage of pre-engineered 
pathway chassis. The power of this approach has been recently demonstrated by 
straightforward design of novel producing strains for the monomer building block 
diaminopentane (Kind et al., 2010) and the chemical chaperone ectoine (Becker et 
al., 2013), both using a metabolic chassis of Corynebacterium glutamicum, 
previously developed for hyper-production of L-lysine (Becker et al., 2011).  
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5 Conclusions and Outlook 
In the present work, E. coli could be successfully engineered for 
biosynthesis of either deoxyviolacein or violacein. Starting from a basic 
deoxyviolacein producer, systems metabolic engineering enabled the identification 
of limitations in the availability of the precursor metabolite L-tryptophan, which was 
subsequently addressed by modifications in the genome for improvement of the 
metabolic fluxes towards this amino acid. The improved deoxyviolacein producer 
was additionally modified to inactivate the catabolism of L-arabinose, so that this 
sugar could be used exclusively for induction of gene expression. After bioprocess 
optimization, 1.6 g L-1 deoxyviolacein could be produced in a fed-batch cultivation 
using glycerol as main carbon source. Subsequent downstream operations 
allowed deoxyviolacein to be recovered at high purity (>99%). By utilizing the 
chassis strain with improved metabolism for L-tryptophan biosynthesis, additional 
integration of the vioD of J. lividum permitted complete redirection of the pathway  
fluxes to produce violacein, without any detectable amounts of deoxyviolacein. 
Similarly, a fed-batch process allowed production of 700 mg L-1 violacein using L-
arabinose as main carbon source. The product could be recovered at high purity 
(>99%) in crystalline form after extraction. A variant of the above mentioned 
violacein producer with disrupted L-arabinose catabolism was also constructed; 
however, due to time constrains, this mutant could not be extensively tested and 
was left out of the present work.     
Additional strategies that can be used to improve the production capabilities 
of the strains constructed should considerer all aspects from gene expression, 
bioprocess optimization, and downstream processes. Usually, optimization of 
processes for production of heterologous products involves the maximization of 
the metabolic capabilities of the producing organism towards the desired product. 
Different approaches are available for this objective. One of these is the 
stabilization of the mRNA related to the pathway of the desired product. This 
objective can be achieved by inserting protective elements at the two ends of the 
mRNA to reduce its degradation speed (Makrides, 1996), thereby allowing 
reduction in the use of inducers of gene expression, and potentially increase 
accumulation of the desired product. Although the violacein and deoxyviolacein 
pathways are functional in E. coli, it can not be ruled out that some limitation 
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regarding codon usage (Makrides, 1996) may be taking place. Analysis of the 
codon usage in the vio genes followed by replacement of rare codons could also 
be helpful for the improvement of production. Complete integration of the 
heterologous pathways into the chromosome would permit reduction of the 
metabolic burden related to plasmid maintenance and the elimination of the use of 
antibiotics, possibly allowing increases of growth and production rates. 
Improvements are also possible from the bioprocess point of view. Experimental 
design can be used to optimize the medium and culturing conditions during batch 
and fed-batch phases of the production processes (Mandenius and Brundin, 
2008). Additionally, as violacein and deoxyviolacein are hydrophobic molecules 
that accumulate in the cells, two-phase systems (Banik et al., 2003) could be 
tested to evaluate if extractive cultivations could improve the production and/or the 
later downstream operations, which accounts to about 60-90% of the cost of most 
biological processes.  
The created violacein and deoxyviolacein producers, which comprise a 
high-flux tryptophan pathway encoded in their genome, are powerful starting 
points to derive other high-value tryptophan-based therapeutics. Prominent 
candidates are rebeccamycin and staurosporine, both important antitumor 
molecules (Howard-Jones and Walsh, 2006). 
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7 Appendix 
All the work described in this section was carried out by the group of Prof. 
Sprenger at the University of Stuttgart, Institute of Microbiology.  
7.1. Supplementary Information 
7.1.1. Construction of strains TRP1 to TRP6 
If not stated otherwise, all strains are based on E. coli BW25113 and were 
obtained by the red recombination method (Datsenko and Wanner, 2000). 
Primers for amplification of gene cassettes (CmR or KmR from plasmids 
pCO1catFRT or pCO1kanFRT see Suppl. Figure 1) and for verification of  
 
 
Suppl. Figure 1. Maps of plasmids pCO1catFRT and pCO1kanFRT with relevant features for the 
present study. Both plasmids are based on vector pJF119EH (Fürste et al., 1986). NotI restriction 
sites (custom-synthesized by GeneArt, Regensburg, Germany) were introduced by site-directed 
mutagenesis 5´upstream of the PTAC promoter and 3´downstream of the transcription terminator 
sequence, 5SrrnBT1T2 to obtain vector pF113. Cm
R
 and Km
R
 gene cassettes, respectively, were 
equipped on both ends with FRT sites and HindIII restriction sites, respectively (Degner and 
Sprenger, unpublished results). 
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chromosomal insertions, deletions, or disruptions are listed in Supplementary 
Table 1. If antibiotic resistance cassettes were integrated, P1-mediated 
transduction could be used to transfer the respective gene disruptions to other 
strains e.g. E. coli MG1655, a parent strain of BW25113 (Datsenko and Wanner, 
2000). 
Supplementary Table 1. Primers used. 
Primer 
ID 
Primers (5’->3’) Target 
27 CAGTCATAGCCGAATAGCCTCTC K1 primer (inside of Km
R
 cassette) 
28 TGGATAATGTTTTTTGCGCCGACATCATAACG
GTTCTGGCAAATATTCTGAAATGTTGTGTAGG
CTGGAGCTGCTTCG 
 
deletion of the trpE gene 
29 ATCGGTTGTACAAAAACTTTCAGTGCCGCCA
GCATTTTCTCTGGCTCATTAATATCATATGAAT
ATCCTCCTTAGTTC 
30 TATTCGACATGTTTAAGGTGGGGATTGGTCC
CTCATCTTCCCATATGTGTAGGCTGGAGCTG
CTTCG 
 
deletion of the sdaA gene 
31 TCACACTGGACTTTGATTGCCAGACCACCGC
G-TGAGGTTTCCATATGAATATCCTCC 
TTAGTTC 
32 GCGGTGGCAATAGCGCGCAGTAC 
screening of the trpE deletion 33 TTTTGAGCTCTGCGCGAGGAACTCACACATTA
G 
34 GGCCTATTTCCCTAAAGGGTTTATTGAG cat-screen (inside of cat- cassette) 
35 TCGCGCCAGTGAAGATGAAGTCTCGG screening of the sdaA deletion 
36 TTTTGAGCTCTGCGCGAGGAACTCACACATTA
G 
deletion of the trpL sequence 
(amplification of left fragment) SacI 
restriction site is underlined 
37 TTTTGGATCCCGTGAACTTGCGTACTAGTTAA
C 
deletion of the trpL sequence (left 
fragment amplification) engineered  
BamHI restriction site is underlined 
38 TTAAACCGGCCGGAATGTTACTGCCAACCAG
CG 
deletion of the trpL sequence 
(amplification of right  fragment) 
engineered EagI restriction site is 
underlined 
39 TTTTGGATCCATTAGAGAATAACAATGCAAAC
AC 
deletion of the trpL sequence (right 
fragment amplification) underlined 
- BamHI restriction site 
40 GAGTAATCCCAGCCCGTACACGTTTTTTATGC
AGGATAATG QuikChange mutagenesis 
(Met293Thr exchange) of trpE 
gene 41 CATTATCCTGCATAAAAAACGTGTACGGGCTG
GGATTACTC 
42 TTAGTACAGCAGACGGGCGCGAATGGTACCC
GGAATAGCTTTCATTGCCTCATATGAATATCC
TCCTTAGTTC deletion of the serA gene 
43 AAGGTATCGCTGGAGAAAGACAAGATTAAGT
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TTCTGCTGGTAGAAGGCGTTTGTGTAGGCTG
GAGCTGCTTCG 
44 TTTTGAGCTCATGGCAAAGGTATCGCTGGAG
AAAG cloning of the serA gene as well as 
screening of serA deletion 
45 TTTTGTCGACTTAGTACAGCAGACGGGCGCG 
46 CGCGCAATATCTGCAAGATTCCGCCCAGATG
GG QuikChange mutagenesis of the 
serA gene Thr372Asp 47 CCCATCTGGGCGGAATCTTGCAGATATTGCG
CG 
48 GACGAACTGGTGTTGGGTAAGCGTATGGAAG
AGCACTTGCGTTTTGCCGCCTGCTCAAGGCG
CACTCCCGTTCTGG  
integration of serA into xyl-locus 
 
integration of serA into xyl-locus 
49 ATTAAAGCTGGGACATTGCTCAGGGTTAATTT
CGCGGCCAGACAATCCCAC 
CAGGGTTATTGTCTCATGAGCG 
50 TGTCCTCACGTAAAGAGCTTGCCAATGCTATT
CGTGCGCTGATTGTGTAGGCTGGAGCTGCTT
CG 
deletion of the tktA gene 
51 TGCCGGAGCAGATTCACCGAAGGTGGTCATA
CCGACGATAGCACATATGAATATCCTCCTTAG
TTC 
52 GGCTGACCGTTGATATTGTTGCCTAGC screening of tktA disruption 
53 TGCAGGCATGAAACCGCGTCTTTTTTCAGATA
AAAAGCGCAATCAGTCGCTCAAGGCGCACTC
CCGTTCTGG  integration of  tktA gene into gal 
locus 54 TAACATTACTCAGCAATAAACTGATATTCCGT
CAGGCTGGAATAAGGATGGCCTTCTGCTTAA
TTTGATGCCTG 
55 TTTCACACAGGAAAGCATATGTCGAGCTCGG
TACCCGGGGATCCTC QuikChange mutagenesis of vector 
pJF119EH- EcoRI >NdeI 56 GGGTACCGAGCTCGACATATGCTTTCCTGTG
TGAAATTGTTATCCGCTC 
57 TTTCACACCGCATACGGTGCACTCTCAGTACA
ATCTGCTCTG  QuikChange mutagenesis of vector 
pJF119EH - deletion of NdeI site at 
position 2421 58 CTGAGAGTGCACCGTATGCGGTGTGAAATAC
CGCAC 
59 TCACACAGGAGATATACATATGTCGAGCTCG
GTACCCGGG  
QuikChange mutagenesis of 
pJF119E NdeI– modification of 
sequence between PTAC promoter 
and start codon to yield pJNNmod 
60 CTCGACATATGTATATCTCCTGTGTGAAATTG
TTATCCGCTCACAATTC 
61 TTAAACCGGCCGGAATGTTACTGCCAACCAG
CG amplification of PTRPtrpE fragment 
for sequencing  62 TTTTGAGCTCTGCGCGAGGAACTCACACATTA
G 
63 CCA GCG AGT GAT AAC GCG CCA C sequencing of PTRPtrpE fragment 
64 ACGGCCAGTTAAGCCATTCATGCCAG 
screening of the tktA deletion  
65 CTCAGCGCACGAATAGCATTGGCAAGC 
66 CCACACGCCACGGTGCGCTTTAG 
screening of the tktA integration 
67 GAG GTG CAA AGG GTG AGT AGA ATG TTC 
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Strain TRP1 (BW25113 ∆sdaA::FRT-Cm-FRT; Table 2): The disruption of 
gene sdaA (encoding a L-serine dehydratase) was accomplished by primers 30 
and 31 (encompassing homologous DNA 5´ upstream and 3´downstream of sdaA) 
to amplify the CmR cassette from pCO1catFRT plasmid. Verification of 
chromosomal integration was by PCR using primers 34 and 35.  
 
 
Suppl. Figure 2. Deletion of trpL gene and mutagenesis of trpE gene in the chromosome of strain 
BW25113. The strain TRP2 (BW25113 ∆trpE::FRT-Km-FRT) was constructed using the red 
recombination method (Datsenko and Wanner, 2000). Disruption of the trpE gene was by insertion 
of an amplified Km
R
 cassette from plasmid pCO1kanFRT (Suppl. Figure 1; Degner and Sprenger, 
unpublished results) and primers 28 and 29. 
 
Strain TRP2 (BW25113 ∆trpE::FRT-Km-FRT, Table 2): The disruption of gene 
trpE (encoding a subunit of anthranilate synthase) was accomplished by primers 
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28 and 29 (encompassing homologous DNA 5´ upstream and 3´ downstream of 
trpE) to amplify the KmR cassette from pCO1kanFRT plasmid.  Verification of 
chromosomal integration was by PCR using primers 32 and 33. Strain TRP2 is 
tryptophan auxotroph. 
Strain TRP3 (BW25113 ∆trpL, trpEfr): Deletion of the trpL sequence was 
carried out by replacing the KmR cassette in strain TRP2 by a PTRP∆trpL-trpE
fr-trpD’ 
fragment. This fragment was created by PCR-splicing (see Suppl. Suppl. Figure 2 
for illustration).  
The left fragment (440 bp) was PCR-amplified using primers 36 and 37. The 
fragment contains the promoter of the trp operon but lacks the leader peptide 
coding trpL region. A SacI restriction site was introduced at the 5´, and a BamHI 
site at the 3´ end. The right fragment (2008 bp) was amplified using the primers 38 
and 39. This DNA fragment contains the complete trpE gene and a 5´portion of the 
trpD gene. A BamHI site was introduced at the 5´, and an EagI site at its 3´end. 
Next, both DNA fragments were digested with BamHI, purified and excised from 
an agarose gel, and ligated in a 1:1 molar ratio. This ligation mix was used as 
template for the next PCR which was performed with the primers 36 and 38. The 
resulting fragment (2448 bp) was purified from an 0.8% (w v-1) agarose gel, and 
blunt-end ligated with pBBR1MCS vector DNA (Kovach et al., 1994) that had been 
linearized with EcoRV, to result in plasmid pTrpED. pTrpED DNA was used as 
template for QuikChange mutagenesis (QuikChange® Site-Directed Mutagenesis 
Kit, Stratagene, San Diego,  USA) to obtain a feedback-resistant variant of 
anthranilate synthase, encoded by trpEfr. QuikChange mutagenesis (Hogrefe et 
al., 2002) was carried out with the primers 40 and 41 to change the codon for Met 
in position 293 to Thr (Caligiuri and Bauerle, 1991). The resulting mutant plasmid 
was designated pTrpED-M293. DNA sequencing revealed additional changes 
which lead to the following amino acid alterations: Asn168Asp, Cys237Arg, and 
Ala478Thr. According to literature, these changes are not detrimental to enzyme 
structure or activity of anthranilate synthase. 
For the replacement of the KmR cassette in strain TRP2 (BW25113 
∆trpE::FRT-Km-FRT), TrpED-M293 plasmid DNA was digested with EagI and SacI 
and used for homologous red recombineering with strain TRP2 (transiently 
carrying pKD46 plasmid) as recipient. As TRP2 is tryptophan-auxotroph, selection 
was done on minimal medium agar plates containing 0.4% (w v-1) glucose and 20 
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μg mL-1 thiamine but lacking L-tryptophan. The resulting clones should have 
exchanged the residing ∆trpE::FRT-Km-FRT by the incoming trpL-trpEfr version. 
To test for feedback-resistant clones, colonies were plated on mineral medium 
(MM) agar plates containing the antimetabolite, 5-methyl-tryptophan (5MT). 
Initially, all tryptophan-prototroph clones showed reduced growth on MM agar 
(0.4% (w v-1) glucose and 20 μg mL-1 thiamine) containing 800 μg mL-1 5MT. After 
2-3 days, papillae arose which could grow in the presence of 5MT. One of these 
papillae was picked and colony-purified. Its chromosomal DNA was isolated and a 
region encompassing the PTRP promoter and the trpE gene was amplified by PCR 
with primers 61 and 62. DNA sequencing (with primer 63) revealed that PTRP 
operator (trpO) region carries a mutation (transition A > G in position -6 relative to 
the transcription start), presumably leading to constitutive and increased 
transcription of the trp operon message. This mutant strain was termed TRP3 
(BW25113 ∆trpL, trpEfr). 
Strain TRP4 (F52 ∆lac::PTACaroFBL-FRT-Km-FRT) is based on an E. coli K-
12 W3110 derivative F52 which was from an unrelated study (Trachtmann and 
Sprenger, unpublished results) and which had obtained the artificial operon 
encoding the aroFBL genes from E. coli by P1-mediated transduction from strain 
F144 (Orf and Bongaerts, unpublished results). Relevant markers for the present 
study are the artificial aroFBL operon under control of PTAC promoter. For 
illustration see Suppl. Figure 3.  
 
 
Suppl. Figure 3. Chromosomal integration of E. coli aroFBL genes as an artificial operon under 
control of a PTAC promoter (Orf and Bongaerts, unpublished results) replacing the resident lacIZYA 
gene cluster. For the DNA sequence of the respective region see Suppl. Figure 4 and text. 
 
The DNA sequence was established and is presented in Suppl. Figure 4. The 
artificial operon is essentially based on plasmid-borne aroFBL genes of E. coli as 
present on vector pF81 (Rüffer et al., 2004) which were assembled under control 
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of PTAC promoter on vector pF113 (see legend of Suppl. Figure 1). Therefrom, a 
NotI fragment containing PTACaroFBL and the termination sequence rrnB5ST1T2 
was excised. Suicide vector pLOI2224 (KmR; (Martinez-Morales et al., 1999) gene 
sequence in Genbank AF172934) was digested with NotI, treated with Klenow 
polymerase to fill-in overlapping sequences and religated. This pLOI2224NotI 
plasmid DNA was double digested with EcoRI plus BamHI and ligated to upstream 
and downstream sequences of the lacIZYA gene cluster from E. coli. As well, FRT 
sites were introduced adjacent to a kanamycin resistance marker and to oriR6K of 
pLOI2224 and a unique NotI site was engineered. Finally the NotI fragment 
containing PTACaroFBL was ligated to yield vector pC102 (Orf and Bongaerts, 
unpublished results). The vector was introduced into strain W3110 wildtype  
 
5´ATGATTCAGTCACAAATTAACCGCAATATTCGTCTTGATCTTGCCGATGCCATTTTGCTCAGCAAAGCTAA
AAAAGATCTCTCATTTGCCGAGATTGCCGACGGCACCGGTCTGGCAGAAGCCTTTGTAACCGCGGCTTTGCTG
GGTCAGCAGGCGCTTCCTGCCGACGCCGCCCGCCTGGTCGGGGCGAAGCTGGATCTCGACGAAGACTCCATTC
TACTGTTGCAGATGATTCCACTGCGTGGCTGCATTGATGACCGTATTCCAACTGACCCAACGATGTATCGTTT
CTATGAAATGTTGCAGGTGTACGGTACAACCCTGAAAGCGTTGGTTCATGAGAAATTTGGCGATGGCATTATT
AGCGCGATTAACTTCAAACTCGACGTTAAGAAAGTGGCGGACCCGGAAGGTGGCGAACGTGCGGTCATCACCT
TAGATGGTAAATATCTGCCGACCAAACCGTTCTGACAGCCATGCGCAACCATCAAAAGACGTTCACGATGCTG
CTGGTACTGGTGCTGATTGGTCTTAATATGCGACCACTGCTCACCTCCGTCGGGCCACTGCTACCGCAATTGC
GCCAGGCGAGCGGAATGAGCTTTAGCGTGGCTGCCCTGTTGACCGCTCTGCCGGTGGTTACCATGGGCGGGCT
GGCGCTGGCCGGAAGCTGGCTTCATCAGCATGTCAGCGAACGTCGCAGTGTCGCCATCAGTCTGTTGCTGATT
GCCGTCGGTGCATTGATGCGTGAGCTTTACCCGCAAAGTGCGCTGCTGCTTAGCAGCGCACTGCTTGGTGGGG
TGGGGATCGGCATCATTCAGGCGGTGATGCCTTCGGTGATTAAACGGCGGTTTCAGCAGCGCACGCCACTGGT
GATGGGGCTGTGGTCCGCGGCTCTGATGGGCGGCGGTGGGCTTGGTGCCGCCATAACGCCCTGGTTAGTTCAA
CATAGCGAAACCTGGTATCAAACACTCGCCTGGTGGGCGCTGCCTGCCGTTGTTGCGCTCTTTGCCTGGTGGT
GGCAAAGCGCCCGCGAGGTCGCCTCTTCCCACAAGACAACAACCACTCCGGTTCGCGTGGTATTCACTCCCCG
CGCGTGGACGCTGGGTGTTTACTTCGGTCTGATTAACGGCGGTTACGCCAGCCTGATTGCCTGGTTACCCGCT
TTCTATATTGAGATTGGTGCCAGCGCGCAGTACAGCGGTTCCTTACTGGCATTGATGACGCTTGGGCAAGCCG
CAGGAGCTTTGCTGATGCCTGCTATGGCTCGCCATCAGGATCGGCGCAAACTGTTAATGCTGGCGCTGGTGTT
ACAACTGGTGGGGTTCTGCGGCTTTATCTGGCTGCCGATGCAATTGCCGGTATTGTGGGCGATGGTGTGTGGG
TTAGGTCTGGGCGGCGCGTTTCCGCTCTGTTTGCTGCTGGCGCTCGATCACTCTGTGCAACCGGCTATTGCTG
GCAAGCTGGTGGCGTTTATGCAGGGAATCGGTTTTATCATCGCCGGGCTTGCCCCGTGGTTTTCTGGCGTGCT
GCGTAGTATCAGCGGCAATTACCTGATGGACTGGGCATTTCATGCGCTGTGCGTCGTTGGGCTGATGATCATA
ACCCTGCGTTTTGCACCAGTACGTTTTCCGCAGCTGTGGGTCAAAGAGGCATGATGCGACGCTTGTTCCTGCG
CTTTGTTCATGCCGGATGCGGCTAATGTAGATCGCTGAACTTGTAGGCCTGATAAGCGCAGCGGAATTCCGGT
CTCCCTATAGTGAGTCGTATTAATTTCGATAAGCCAGATCAAGCTTGTCGACCAATTCGAAGTTCCTATACTT
TCTAGAGAATAGGAACTTCCGGGATCAATTCATCGCGGAATTAATTCGAGCTCGGGAAGATCTTCCGGAAGAT
CTTCCCCGGGGATCCGCGGCCGCATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATC
ATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGAATTCGAGCATAAACA
GGATCGCCATCATGCAAAAAGACGCGCTGAATAACGTACATATTACCGACGAACAGGTTTTAATGACTCCGGA
ACAACTGAAGGCCGCTTTTCCATTGAGCCTGCAACAAGAAGCCCAGATTGCTGACTCGCGTAAAAGCATTTCA
GATATTATCGCCGGGCGCGATCCTCGTCTGCTGGTAGTATGTGGTCCTTGTTCCATTCATGATCCGGAAACTG
CTCTGGAATATGCTCGTCGATTTAAAGCCCTTGCCGCAGAGGTCAGCGATAGCCTCTATCTGGTAATGCGCGT
CTATTTTGAAAAACCCCGTACCACTGTCGGCTGGAAAGGGTTAATTAACGATCCCCATATGGATGGCTCTTTT
GATGTAGAAGCCGGGCTGCAGATCGCGCGTAAATTGCTGCTTGAGCTGGTGAATATGGGACTGCCACTGGCGA
CGGAAGCGTTAGATCCGAATAGCCCGCAATACCTGGGCGATCTGTTTAGCTGGTCAGCAATTGGTGCTCGTAC
AACGGAATCGCAAACTCACCGTGAAATGGCCTCCGGGCTTTCCATGCCGGTTGGTTTTAAAAACGGCACCGAC
GGCAGTCTGGCAACAGCAATTAACGCTATGCGCGCCGCCGCCCAGCCGCACCGTTTTGTTGGCATTAACCAGG
CAGGGCAGGTTGCGTTGCTACAAACTCAGGGGAATCCGGACGGCCATGTGATCCTGCGCGGTGGTAAAGCGCC
GAACTATAGCCCTGCGGATGTTGCGCAATGTGAAAAAGAGATGGAACAGGCGGGACTGCGCCCGTCTCTGATG
GTAGATTGCAGCCACGGTAATTCCAATAAAGATTATCGCCGTCAGCCTGCGGTGGCAGAATCCGTGGTTGCTC
AAATCAAAGATGGCAATCGCTCAATTATTGGTCTGATGATCGAAAGTAATATCCACGAGGGCAATCAGTCTTC
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CGAGCAACCGCGCAGTGAAATGAAATACGGTGTATCCGTAACCGATGCCTGCATTAGCTGGGAAATGACCGAT
GCCTTGCTGCGTGAAATTCATCAGGATCTGAACGGGCAGCTGACGGCTCGCGTGGCTTAAGAGGTTTATTATG
GTTGCTGAATTGACCGCATTACGCGATCAAATTGATGAAGTCGATAAAGCGCTGCTGAATTTATTAGCGAAGC
CCCGGGGGATCCGTAATTAAGGTGGATGTCGCGTTATGGAGAGGATTGTCGTTACTCTCGGGGAACGTAGTTA
CCCAATTACCATCGCATCTGGTTTGTTTAATGAACCAGCTTCATTCTTACCGCTGAAATCGGGCGAGCAGGTC
ATGTTGGTCACCAACGAAACCCTGGCTCCTCTGTATCTCGATAAGGTCCGCGGCGTACTTGAACAGGCGGGTG
TTAACGTCGATAGCGTTATCCTCCCTGACGGCGAGCAGTATAAAAGCCTGGCTGTACTCGATACCGTCTTTAC
GGCGTTGTTACAAAAACCGCATGGTCGCGATACTACGCTGGTGGCGCTTGGCGGCGGCGTAGTGGGCGATCTG
ACCGGCTTCGCGGCGGCGAGTTATCAGCGCGGTGTCCGTTTCATTCAAGTCCCGACGACGTTACTGTCGCAGG
TCGATTCCTCCGTTGGCGGCAAAACTGCGGTCAACCATCCCCTCGGTAAAAACATGATTGGCGCGTTCTACCA
ACCTGCTTCAGTGGTGGTGGATCTCGACTGTCTGAAAACGCTTCCCCCGCGTGAGTTAGCGTCGGGGCTGGCA
GAAGTCATCAAATACGGCATTATTCTTGACGGTGCGTTTTTTAACTGGCTGGAAGAGAATCTGGATGCGTTGT
TGCGTCTGGACGGTCCGGCAATGGCGTACTGTATTCGCCGTTGTTGTGAACTGAAGGCAGAAGTTGTCGCCGC
CGACGAGCGCGAAACCGGGTTACGTGCTTTACTGAATCTGGGACACACCTTTGGTCATGCCATTGAAGCTGAA
ATGGGGTATGGCAATTGGTTACATGGTGAAGCGGTCGCTGCGGGTATGGTGATGGCGGCGCGGACGTCGGAAC
GTCTCGGGCAGTTTAGTTCTGCCGAAACGCAGCGTATTATAACCCTGCTCAAGCGGGCTGGGTTACCGGTCAA
TGGGCCGCGCGAAATGTCCGCGCAGGCGTATTTACCGCATATGCTGCGTGACAAGAAAGTCCTTGCGGGAGAG
ATGCGCTTAATTCTTCCGTTGGCAATTGGTAAGAGTGAAGTTCGCAGCGGCGTTTCGCACGAGCTTGTTCTTA
ACGCCATTGCCGATTGTCAATCAGCGTAACAACAAGAAAGCTTCTATTGGGGAAAACCCACGATGACACAACC
TCTTTTTCTGATCGGGCCTCGGGGCTGTGGTAAAACAACGGTCGGAATGGCCCTTGCCGATTCGCTTAACCGT
CGGTTTGTCGATACCGATCAGTGGTTGCAATCACAGCTCAATATGACGGTCGCGGAGATCGTCGAAAGGGAAG
AGTGGGCGGGATTTCGCGCCAGAGAAACGGCGGCGCTGGAAGCGGTAACTGCGCCATCCACCGTTATCGCTAC
AGGCGGCGGCATTATTCTGACGGAATTTAATCGTCACTTCATGCAAAATAACGGGATCGTGGTTTATTTGTGT
GCGCCAGTATCAGTCCTGGTTAACCGACTGCAAGCTGCACCGGAAGAAGATTTACGGCCAACCTTAACGGGAA
AACCGCTGAGCGAAGAAGTTCAGGAAGTGCTGGAAGAACGCGATGCGCTATATCGCGAAGTTGCGCATATTAT
CATCGACGCAACAAACGAACCCAGCCAGGTGATTTCTGAAATTCGCAGCGCCCTGGCACAGACGATCAATTGT
TGATTTTCGAGCGCAAGCTTCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAAC
GCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAA
CTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGGCA
TCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTC
CTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGAC
GCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACA
AACTCTTTTGTTTATTTTTCTAAATACATTCAAATATGCGGCCGCCTGAATTGACTCTCTTCCGGGCGCTATC
ATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCAACGTAAATGCATGCCGCTTCGCCTTCCGGCCA
CCAGAATAGCCTGCGATTCAACCCCTTCTTCGATCTGTTTTGCTACCCGTTGTAGCGCCGGAAGATGCTTTTC
CGCTGCCTGTTCAATGGTCATTGCGCTCGCCATATACACCAGATTCAGACAGCCAATCACCCGTTGTTCACTG
CGCAGCGGTACGGCGATAGAGGCGATCTTCTCCTCCTGATCCCAGCCGCGGTAGTTCTGTCCGTAACCCTCTT
TGCGCGCGCGCGCCAGAATGGCTTCCAGCTTTAACGGTTCCCGTGCCAGTTGATAGTCATCACCGGGGCGGGA
GGCTAACATTTCGATTAATTCCTTGCGGTCTTGTTCCGGGCAAAAGGCCAGCCAGGTCAGGCCCGAGGCGGTT
TTCAGAAGCGGCAAACGTCGCCCGACCATTGCCCGGTGAAAGGATAAGCGGCTGAAACGGTGAGTGGTTTCGC
GTACCACCATTGCATCAACATCCAGCGTGGACACATCTGTCGGCCATACCACTTCGCGCAACAGATCGCCCAG
CAGTGGGGCCGCCAGTGCAGAAATCCACTGTTCGTCACGAAATCCTTCGCTTAATTGCCGCACTTTGATGGTC
AGTCGAAAACTATCATCGGAGGGGCTACGGCGGACATATCCCTCTTCCTGCAGCGTCTCCAGCAGTCGCCGCA
CAGTGGTGCGATGCAGGCCGCTGAGTTCCGCCAGCAGCCCGACGCTGGCACCGCCATCAAGTTTATTTAACAT
ATTTAATAACATTAGACCGCGGGTTAAGCCGCGCACGGTTTTGTATTCCGTCTGCTCATTGTTCTGCAT3’ 
 
Suppl. Figure 4. DNA sequence of chromosomal PTACaroFBL region. 
 
(LJ110; (Zeppenfeld et al., 2000)) and selection was on resistance against 
kanamycin. KmR recombinants were screened for loss of the chromosomal 
lacIZYA genes (lactose-negative phenotype) and verified by PCR. Using phage 
P1-assisted transduction, the chromosomal region could be transferred to other E. 
coli recipient strains. To remove the KmR cassette, the FLP recombination method 
using plasmid pCP20 (Cherepanov and Wackernagel, 1995) was used. Suppl. 
Figure 3 depicts the chromosomal gene order after FLP recombination. The DNA 
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sequence of the chromosomal region ∆lac::PTACaroFBL-FRT-Km-FRT was finally 
verified by DNA sequencing. The sequence is given in Suppl. Figure 4. 
Strain TRP5 (BW25113 Ara+ ∆tktA ∆gal::PTACtktA-FRT-Cm-FRT): First, strain 
BW25113 strain was made arabinose-positive by P1-mediated transduction using 
a P1 lysate grown on strain LJ110 (Zeppenfeld et al., 2000). Selection was carried 
out on plates with MM and 0.4% (w v-1) L-arabinose. This strain was termed 
BW25113Ara+. Next, the residing tktA gene was deleted using the KmR cassette 
from plasmid pCO1kanFRT (Suppl. Figure 1) and using the primers 50 and 51. 
The PCR amplicon was introduced by electroporation into strain BW25113Ara+ 
and selection was for Km resistance. The disruption was confirmed by PCR using 
primers 52 and 27. Removal of the KmR cassette was carried out by FLP 
recombinase with transient transformation by plasmid pCP20 to give strain 
BW25113Ara+ tktA. Verification of the deletion was performed with PCR using 
primers 64 and 65. Wild type tktA gene from E. coli K-12 (Sprenger et al., 1995) 
was cloned on plasmid pF113 to give plasmid pC18 (Degner and Sprenger, 
unpublished results). A CmR cassette from pCO1catFRT (Suppl. Figure 1) was 
prepared by HindIII digestion and gel purification and ligated to vector pC18 
(linearized with HindIII), downstream of the tktA gene. This gene construct was 
then PCR amplified using primers 53 and 54 which contain homologous DNA 
sequences to the gal locus of E. coli chromosome. The resulting PCR amplicon 
was used to transform strain BW25113Ara+ tktA to resistance against 
chloramphenicol. CmR transformants were checked for their Tkt-positive 
phenotype and verified by PCR using primers 66 and 67.  
Strain TRP6 (BW25113 ∆serA ∆xyl::PTACserA
fr-FRT-Km-FRT): Deletion of 
the chromosomal serA gene was carried out by the replacement of the gene with 
the KmR cassette which had been PCR-amplified from pCO1kanFRT plasmid with 
primers 42 and 43. KmR clones were verified by PCR screening with primers 44 
and 45. For chromosomal integration of a serA gene encoding a feedback-
resistant 3-phosphoglycerate dehydrogenase (serAfr), pJA-serA plasmid was 
constructed first. The serA gene was PCR amplified from the LJ110 chromosome 
using the primers 44 and 45 and cloned into SacI and SalI restriction site in the 
pJF119EH vector (Fürste et al., 1986) under control of the PTAC promoter. A feed-
back resistance of the protein was engineered by QuikChange mutagenesis 
(Hogrefe et al., 2002). The codon for Thr at position 372 was changed to encode 
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Asp (Thr372Asp) to yield an enzyme (3-phosphoglycerate dehydrogenase) which 
is feedback-resistant against L-serine (Maier and Flinspach). Site-directed PCR 
mutagenesis was performed with the primers 46 and 47 (pJF119serAfr). The KmR 
cassette from pCO1kanFRT was ligated to pJF119serAfr (linearized with HindIII) 
downstream of the serAfr gene to yield pJF119serAfr-FRT-Km-FRT. For 
chromosomal integration, the xyl locus was chosen and strain BW25113serA 
was the recipient. The PTACserA
fr-FRT-Km-FRT region was PCR-amplified from 
pJF119serAfr-FRT-Km-FRT plasmid with primers 48 and 49. The selection was 
carried out on plates with LB and Km. KmR clones were tested on MacConkey 
agar with 1% (w v-1) xylose (pale colonies due to loss of xylose catabolism) and on 
MM agar containing kanamycin and glucose. 
 
7.1.2. Cloning of vector pJNNmod 
Plasmid vector pJNNmod is based on plasmid pJF119EH (Fürste et al., 
1986). First, an EcoRI site (in the polylinker region) of pJF119EH was changed to 
NdeI site by QuikChange mutagenesis with primers 55 and 56. Next, the resident  
 
  
 
Suppl. Figure 5. Map of plasmid pJNNmod. The plasmid is based upon pJF119EH (Fürste et al., 
1986). The multiple cloning site has been changed to contain restriction sites for the following 
enzymes: NdeI-KpnI-BamHI-XbaI-SphI-HindIII. (Trachtmann and Sprenger, unpublished results). 
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NdeI site was removed by QuikChange mutagenesis with primers 57 and 58 to 
yield pJNN plasmid. To optimize the distance between the PTAC promoter and the 
start codon, this region was also modified by the QuikChange method using 59 
and 60 as primers for this step. Ultimately, the pJNNmod vector (Suppl. Figure 5) 
was constructed. 
 
  
 
 
